EP1112377A4 - Nukleinsäure-gekoppelte kolorimetrische analytdetektoren - Google Patents
Nukleinsäure-gekoppelte kolorimetrische analytdetektorenInfo
- Publication number
- EP1112377A4 EP1112377A4 EP99930522A EP99930522A EP1112377A4 EP 1112377 A4 EP1112377 A4 EP 1112377A4 EP 99930522 A EP99930522 A EP 99930522A EP 99930522 A EP99930522 A EP 99930522A EP 1112377 A4 EP1112377 A4 EP 1112377A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- biopolymeric
- nucleic acid
- materials
- liposomes
- pda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 169
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 142
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 141
- 239000000126 substance Substances 0.000 title description 33
- 238000004458 analytical method Methods 0.000 title description 9
- 239000000463 material Substances 0.000 claims abstract description 407
- 239000002502 liposome Substances 0.000 claims abstract description 311
- 238000000034 method Methods 0.000 claims abstract description 190
- 239000003446 ligand Substances 0.000 claims abstract description 158
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 150000002632 lipids Chemical class 0.000 claims description 142
- 239000000178 monomer Substances 0.000 claims description 126
- 108020004414 DNA Proteins 0.000 claims description 91
- 239000012491 analyte Substances 0.000 claims description 81
- 239000002019 doping agent Substances 0.000 claims description 69
- 230000008859 change Effects 0.000 claims description 66
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 claims description 65
- 102000004190 Enzymes Human genes 0.000 claims description 59
- 108090000790 Enzymes Proteins 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- -1 antibodies Substances 0.000 claims description 47
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 43
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 244000052769 pathogen Species 0.000 claims description 32
- 238000000429 assembly Methods 0.000 claims description 26
- 230000000712 assembly Effects 0.000 claims description 26
- 150000002270 gangliosides Chemical class 0.000 claims description 26
- 239000011521 glass Substances 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 150000001720 carbohydrates Chemical class 0.000 claims description 23
- 235000014633 carbohydrates Nutrition 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- ZPUDRBWHCWYMQS-UHFFFAOYSA-N pentacosa-10,12-diynoic acid Chemical compound CCCCCCCCCCCCC#CC#CCCCCCCCCC(O)=O ZPUDRBWHCWYMQS-UHFFFAOYSA-N 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 12
- 244000045947 parasite Species 0.000 claims description 12
- 210000005239 tubule Anatomy 0.000 claims description 12
- 229920005654 Sephadex Polymers 0.000 claims description 11
- 239000012507 Sephadex™ Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 claims description 11
- 239000003599 detergent Substances 0.000 claims description 10
- 125000001165 hydrophobic group Chemical group 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 244000052637 human pathogen Species 0.000 claims description 8
- 206010022000 influenza Diseases 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- KTCYROIQAAHHIE-UHFFFAOYSA-N docosa-5,7-diynoic acid Chemical compound CCCCCCCCCCCCCCC#CC#CCCCC(O)=O KTCYROIQAAHHIE-UHFFFAOYSA-N 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 6
- 239000004809 Teflon Substances 0.000 claims description 6
- 229920006362 Teflon® Polymers 0.000 claims description 6
- 150000003862 amino acid derivatives Chemical group 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 239000010931 gold Substances 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229920000123 polythiophene Polymers 0.000 claims description 6
- 229930192474 thiophene Natural products 0.000 claims description 6
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 102000003960 Ligases Human genes 0.000 claims description 5
- 108090000364 Ligases Proteins 0.000 claims description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 5
- 229930183167 cerebroside Natural products 0.000 claims description 5
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 5
- 229940009976 deoxycholate Drugs 0.000 claims description 5
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002113 octoxynol Polymers 0.000 claims description 5
- 229940066429 octoxynol Drugs 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 5
- 150000003577 thiophenes Chemical class 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- WDRZVZVXHZNSFG-UHFFFAOYSA-N 1-ethenylpyridin-1-ium Chemical compound C=C[N+]1=CC=CC=C1 WDRZVZVXHZNSFG-UHFFFAOYSA-N 0.000 claims description 4
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 4
- 102000004856 Lectins Human genes 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 108010017842 Telomerase Proteins 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 150000003926 acrylamides Chemical class 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 4
- 239000012503 blood component Substances 0.000 claims description 4
- 229940073499 decyl glucoside Drugs 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 150000003949 imides Chemical class 0.000 claims description 4
- 125000003010 ionic group Chemical group 0.000 claims description 4
- 239000002523 lectin Substances 0.000 claims description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
- 239000010445 mica Substances 0.000 claims description 4
- 229910052618 mica group Inorganic materials 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 150000003233 pyrroles Chemical class 0.000 claims description 4
- 150000003673 urethanes Chemical class 0.000 claims description 4
- 229960000834 vinyl ether Drugs 0.000 claims description 4
- KPYCVQASEGGKEG-UHFFFAOYSA-N 3-hydroxyoxolane-2,5-dione Chemical compound OC1CC(=O)OC1=O KPYCVQASEGGKEG-UHFFFAOYSA-N 0.000 claims description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 3
- 108020004566 Transfer RNA Proteins 0.000 claims description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 3
- 150000001735 carboxylic acids Chemical group 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 108020004418 ribosomal RNA Proteins 0.000 claims description 3
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 3
- 150000004043 trisaccharides Chemical class 0.000 claims description 3
- 208000007089 vaccinia Diseases 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- QBHFVMDLPTZDOI-UHFFFAOYSA-N dodecylphosphocholine Chemical compound CCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C QBHFVMDLPTZDOI-UHFFFAOYSA-N 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 125000002534 ethynyl group Chemical class [H]C#C* 0.000 claims 2
- NVNPEYQWKCQBBU-ADMXJUBYSA-N (2r,4s,5r,6r)-2-[(2s,3s,4r,5r,6s)-2-[(2r,3s,4s,5s,6s)-3-acetamido-2-[(2s,3r,4s,5s,6r)-4-[(2r,4s,5r,6r)-5-amino-2-carboxy-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxan-2-yl]oxy-6-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-1-(octadecanoyl Chemical compound O[C@@H]1[C@@H](O)[C@H](OC(CNC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)CO)C(O)=O)C(O)=O)[C@H](O)[C@H](CO)O3)O)[C@H](O)[C@H](CO)O2)NC(C)=O)[C@H](CO)O1 NVNPEYQWKCQBBU-ADMXJUBYSA-N 0.000 claims 1
- 229920000015 polydiacetylene Polymers 0.000 abstract description 208
- 238000001514 detection method Methods 0.000 abstract description 102
- 239000012528 membrane Substances 0.000 abstract description 65
- 239000002052 molecular layer Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 168
- 239000000243 solution Substances 0.000 description 124
- 230000004044 response Effects 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 78
- 239000000523 sample Substances 0.000 description 73
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 72
- 229910001868 water Inorganic materials 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- 229940088598 enzyme Drugs 0.000 description 55
- 229920000642 polymer Polymers 0.000 description 53
- 238000006116 polymerization reaction Methods 0.000 description 48
- 239000007787 solid Substances 0.000 description 47
- 230000000694 effects Effects 0.000 description 45
- 239000002904 solvent Substances 0.000 description 44
- 239000000758 substrate Substances 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000007792 addition Methods 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 39
- 230000000295 complement effect Effects 0.000 description 39
- 239000000499 gel Substances 0.000 description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
- 230000035945 sensitivity Effects 0.000 description 36
- 239000002356 single layer Substances 0.000 description 36
- 230000007704 transition Effects 0.000 description 36
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 35
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 34
- 238000009396 hybridization Methods 0.000 description 34
- 239000012071 phase Substances 0.000 description 33
- 230000003993 interaction Effects 0.000 description 29
- 239000011159 matrix material Substances 0.000 description 28
- 230000007246 mechanism Effects 0.000 description 28
- 238000010348 incorporation Methods 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 108010049048 Cholera Toxin Proteins 0.000 description 21
- 102000009016 Cholera Toxin Human genes 0.000 description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 21
- 238000000862 absorption spectrum Methods 0.000 description 21
- 239000000306 component Substances 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 18
- 230000009102 absorption Effects 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 17
- 239000007983 Tris buffer Substances 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 17
- 239000012855 volatile organic compound Substances 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 16
- 239000003960 organic solvent Substances 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 16
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 230000002209 hydrophobic effect Effects 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 238000000527 sonication Methods 0.000 description 15
- 102000005548 Hexokinase Human genes 0.000 description 14
- 108700040460 Hexokinases Proteins 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 102000015439 Phospholipases Human genes 0.000 description 13
- 108010064785 Phospholipases Proteins 0.000 description 13
- 238000003491 array Methods 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 239000003053 toxin Substances 0.000 description 13
- 231100000765 toxin Toxicity 0.000 description 13
- 108700012359 toxins Proteins 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 238000006555 catalytic reaction Methods 0.000 description 12
- 230000008878 coupling Effects 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000008707 rearrangement Effects 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 102000014384 Type C Phospholipases Human genes 0.000 description 11
- 108010079194 Type C Phospholipases Proteins 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 241000712461 unidentified influenza virus Species 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 102000011420 Phospholipase D Human genes 0.000 description 10
- 108090000553 Phospholipase D Proteins 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000007899 nucleic acid hybridization Methods 0.000 description 9
- 238000003980 solgel method Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 8
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 8
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 229910044991 metal oxide Inorganic materials 0.000 description 8
- 150000004706 metal oxides Chemical class 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 150000008300 phosphoramidites Chemical class 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- PYJJCSYBSYXGQQ-UHFFFAOYSA-N trichloro(octadecyl)silane Chemical compound CCCCCCCCCCCCCCCCCC[Si](Cl)(Cl)Cl PYJJCSYBSYXGQQ-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- GUJDUXMBBAOBHN-UHFFFAOYSA-N 6-(dimethylamino)-n-(2h-tetrazol-5-yl)pyrazine-2-carboxamide Chemical compound CN(C)C1=CN=CC(C(=O)NC2=NNN=N2)=N1 GUJDUXMBBAOBHN-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 6
- 125000002843 carboxylic acid group Chemical group 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229920000547 conjugated polymer Polymers 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- 241000606161 Chlamydia Species 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000005289 controlled pore glass Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000003380 quartz crystal microbalance Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000010897 surface acoustic wave method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 241000607626 Vibrio cholerae Species 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 239000000075 oxide glass Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 150000003141 primary amines Chemical group 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 3
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 3
- DIEDVCMBPCRJFQ-UHFFFAOYSA-N 10,12-tricosadiynoic acid Chemical compound CCCCCCCCCCC#CC#CCCCCCCCCC(O)=O DIEDVCMBPCRJFQ-UHFFFAOYSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 108010029541 Laccase Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000012565 NMR experiment Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 241000702263 Reovirus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000004630 atomic force microscopy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 150000001841 cholesterols Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- FNZINNGYZQYQHC-UHFFFAOYSA-N pentacosa-5,7-diynoic acid Chemical compound CCCCCCCCCCCCCCCCCC#CC#CCCCC(O)=O FNZINNGYZQYQHC-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000004756 silanes Chemical class 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000002277 temperature effect Effects 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 241001125671 Eretmochelys imbricata Species 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000701363 Homo sapiens Phospholipid-transporting ATPase IC Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102100030448 Phospholipid-transporting ATPase IC Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000194021 Streptococcus suis Species 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 150000000475 acetylene derivatives Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 150000002137 ergosterols Chemical class 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229940052303 ethers for general anesthesia Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000013546 insoluble monolayer Substances 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000013547 langmuir monolayer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- DZLWMPMXBUHMQV-UHFFFAOYSA-N pentacosa-2,4-diynoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC#CC#CC(O)=O DZLWMPMXBUHMQV-UHFFFAOYSA-N 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 239000013545 self-assembled monolayer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- CPUDPFPXCZDNGI-UHFFFAOYSA-N triethoxy(methyl)silane Chemical compound CCO[Si](C)(OCC)OCC CPUDPFPXCZDNGI-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001429 visible spectrum Methods 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- VXUOFDJKYGDUJI-UHFFFAOYSA-N (2-hydroxy-3-tetradecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-UHFFFAOYSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical class O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical class OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NJDPBWLDVFCXNP-UHFFFAOYSA-N 2-cyanoethyl dihydrogen phosphate Chemical compound OP(O)(=O)OCCC#N NJDPBWLDVFCXNP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- UUEWCQRISZBELL-UHFFFAOYSA-N 3-trimethoxysilylpropane-1-thiol Chemical compound CO[Si](OC)(OC)CCCS UUEWCQRISZBELL-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 241000700606 Acanthocephala Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000272079 Bungarus multicinctus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100050026 Enterobacteria phage T4 y01J gene Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241001125831 Istiophoridae Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000243981 Onchocerca Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- BFRHZCVPRCBRDG-UHFFFAOYSA-N P(=O)(O)(O)OCCCCCCCCCC#CC#CCCCCCCCCCCCCC.P(=O)(O)(O)O Chemical compound P(=O)(O)(O)OCCCCCCCCCC#CC#CCCCCCCCCCCCCC.P(=O)(O)(O)O BFRHZCVPRCBRDG-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 108010002176 Phospholipases A Proteins 0.000 description 1
- 102000000571 Phospholipases A Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000242594 Platyhelminthes Species 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000607594 Vibrio alginolyticus Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000004937 angle-resolved X-ray photoelectron spectroscopy Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 229940099459 n-acetylmethionine Drugs 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 125000000371 nucleobase group Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- MYHOHFDYWMPGJY-UHFFFAOYSA-N pentafluorobenzoyl chloride Chemical compound FC1=C(F)C(F)=C(C(Cl)=O)C(F)=C1F MYHOHFDYWMPGJY-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 150000003613 toluenes Chemical class 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100001234 toxic pollutant Toxicity 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- YIQCSJRVSYPZPP-UHFFFAOYSA-N tricosa-2,4-diynoic acid Chemical compound CCCCCCCCCCCCCCCCCCC#CC#CC(O)=O YIQCSJRVSYPZPP-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- LYTCVQQGCSNFJU-PJLYXUTNSA-N β-bungarotoxin Chemical compound C([C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=CC[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-PJLYXUTNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention relates to methods and compositions for the direct detection of analytes using color changes that occur in biopolymeric material in response to selective binding of analytes.
- DNA synthesis via the automated solid-phase method whereby the DNA fragment is built up by the sequential addition of activated nucleotides to a growing chain that is linked to an insoluble support, has provided for the synthesis of DNA chains of up to 100 nucleotides long at an approximate rate of 10 minutes per base.
- Such artificial DNA strands with known sequence, the single stranded probe DNA have been used to find the complementary counterpart in DNA samples by hybridization. Above a certain temperature (T m ) the DNA double helix "melts" to form two complementary single strands which recombine upon cooling. If a single strand from the sample has the complementary sequence to the probe DNA they can hybridize to form a double helix.
- Detection of the DNA hybridization process is important for the development of methods and compositions for DNA synthesis and detection of specific nucleic acid sequences (e.g., detection of mutations, pathogens, and particular alleles).
- One approach for detecting DNA hybridization utilizes a quartz crystal microbalance, which is a very sensitive device to measure mass changes in the nanogram regime (Okahata et al, J. Am. Chem. Soc.
- DNA hybridization between a synthetic oligodeoxynucleotide of known sequence and its complement in a given sample provides a powerful tool for the detection and sequencing of DNA and RNA.
- the hybridization event itself is usually monitored by introducing fluorescent markers and radioactive labels or by applying antibody assays and enzyme reactions to the specifically modified DNA (or RNA) pair, which generalh requires labor intensive and time consuming multistep procedures.
- analyte detectors that provide for DNA detection that can be visually monitored by the naked eye, thus, making any further detection procedures ancillary or unnecessary.
- the present invention relates to methods and compositions for the direct detection of analytes using color changes that occur in biopolymeric material in response to selective binding of analytes.
- the biopolymeric material comprises self- assembling monomers.
- the self-assembling monomers are lipids.
- the present invention contemplates biopolymeric materials comprising a plurality of polymerized self-assembling monomers and one or more nucleic acid ligands, wherein said biopolymeric materials change color in the presence of an analyte.
- the nucleic acids have affinity for an analyte.
- the nucleic acid ligands are single stranded nucleic acid sequences.
- the nucleic acid ligands are linked to said polymerized self-assembling monomers through one or more co ⁇ alent bonds.
- the covalent bonds are selected from the group consisting of amine bonds, thiol bonds, and aldehyde bonds.
- the biopolymeric materials contains nucleic acids as ligands that have affinity for an analyte.
- the nucleic acid ligands have affinity for an analyte selected from the group of nucleic acid molecules, enzymes, pathogens, drugs, receptor ligands, antigens, ions, proteins, hormones. blood components, antibodies, and lectins.
- the analytes are nucleic acid molecules are from any organism (including microorganisms, including, but not limited to bacteria, fungi, viruses, etc.), cell, plasmid, or expression vector.
- the analytes which are nucleic acid molecules are selected from ribosomal RNA. transfer RNA, messenger RNA. intron RNA, double stranded RNA, single stranded RNA. single stranded DNA, double stranded DNA, DNA-RNA hybrid molecules. PNA,
- the analytes are enzymes including, but not limited to, polymerases, nucleases, ligases, telomerases, and transcription factors.
- the present invention also contemplates biopolymeric materials comprising nucleic acid ligands that have affinity for analytes that are pathogens. It is not intended that the present invention be limited to any particular pathogen analyte(s), as a variety of pathogen analytes are contemplated.
- the pathogens are selected from viruses, bacteria, parasites, and fungi.
- the pathogens are viruses selected from influenza, rubella, varicella-zoster, hepatitis A. hepatitis B, other hepatitis viruses, herpes simplex, polio, smallpox, human immunodeficiency virus, vaccinia, rabies, Epstein Barr. retroviruses.
- the pathogens are bacteria selected from Escherichia coli, Mycobacterium tuberculosis, Salmonella, Chlamydia and Streptococcus.
- the pathogens are parasites selected from Plasmodium, Trypanosoma, Toxoplasma gondii, and Onchocerca.
- the present invention be limited to the specific genera and/or species listed above.
- the biopolymeric materials comprise biopolymeric films. In other embodiments, the biopolymeric materials comprise biopolymeric liposomes. In yet other embodiments, the biopolymeric materials are selected from the group consisting of tubules, braided assemblies, lamellar assemblies, helical assemblies, fiber-like assemblies, solvated rods, and solvated coils.
- the self-assembling monomers of the biopolymeric material of the present invention comprise diacetylene monomers.
- the diacetylene monomers are selected from the group consisting of 5,7-docosadiynoic acid, 5,7-pentacoadiynoic acid, 10,12-pentacosadiynoic acid, and combinations thereof, although all diacetylene monomers are contemplated by the present invention.
- the self-assembling monomers are selected from the group consisting of acetylenes, alkenes. thiophenes, polythiophenes. imides, acrylamides, methacrylates, vinylether. malic anhydride, urethanes.
- the self-assembling monomers contain head groups selected from the group consisting of carboxylic acid, hydroxyl groups, amine groups, amino acid derivatives, and hydrophobic groups, although other head groups are also contemplated by the present invention.
- the present invention also contemplates biopolymeric materials further comprising dopant materials.
- dopant materials are selected from the group consisting of surfactants, polysorbate, octoxynol, sodium dodecyl sulfate, polyethylene glycol, zwitterionic detergents, dec) lglucoside. deoxycholate, diacetylene derivatives, phosphatidylserine. phosphatidylinositol, phosphatidylethanolamme, phosphatidylcholine, phosphatidylglycerol.
- the dopant material is a diacetylene derivative selected from the group consisting of sialic acid-derived diacetylene. lactose-derived diacetylene, and amino-derived diacetylene.
- the present invention also contemplates biopolymeric materials further comprising one or more non-nucleic acid ligands.
- the present invention be limited to certain non-nucleic acid ligands, as a variety of non-nucleic acid ligands are contemplated.
- the non-nucleic acid ligands are selected from the group consisting of carbohydrates, proteins, drugs, chromophores, antigens, chelating compounds, molecular recognition complexes, ionic groups, polymerizable groups, linker groups, electron donors, electron acceptor groups, hydrophobic groups, hydrophilic groups, receptor binding groups, trisaccharides, tetrasaccharides, ganglioside G M
- . ganglioside G TH flourish sialic acid, and combinations thereof.
- the biopolymeric materials further comprise a support, wherein the biopolymeric materials are immobilized to the support.
- the support is selected from the group consisting of polystyrene, polyethylene, teflon, mica, sephadex, sepharose, polyacrynitriles, filters, glass, gold, silicon chips, and silica.
- the support comprises porous silica glass, wherein the biopolymeric materials are immobilized within the porous silica glass, although the present invention contemplates a variety of other supports.
- the present invention also provides devices comprising one or more of the biopolymeric materials described above, wherein the biopolymeric materials are immobilized to the device.
- the present invention further provides methods for detecting the presence of an analyte.
- the methods comprise the steps of providing biopolymeric materials comprising a plurality of polymerized lipid monomers and one or more ligands wherein the biopolymeric materials change color in the presence of analyte, and a sample suspected of containing an analyte; contacting the biopolymeric materials with the sample; and detecting a color change in the biopolymeric materials.
- the ligands are nucleic acid ligands.
- the present invention provides biopolymeric materials for analyses such as methods to colorimetrically detect DNA hybridization.
- the present invention also provides methods for detecting the presence of nucleic acid hybridization.
- the methods comprise the steps of providing one or more nucleic acid hybrids to be detected, and biopolymeric materials comprising a plurality of polymerized lipid monomers and one or more ligands with affinity for the nucleic acid to be detected; contacting the biopolymeric materials with the nucleic acid to be detected; and detecting the presence of nucleic acid.
- Figure 1 shows a schematic representation of biopolymeric films.
- Y is a centrosymmetric multilayer film, while films X and Z are noncentrosymmetric multilayers.
- Figure 2 shows a schematic representation of biopolymeric liposomes.
- Part A is a cross-section two-dimensional view and part B is a three-dimensional view of half of a liposome.
- Figure 3 shows biopolymeric 1) liposomes and 2) films comprising the same biopolymeric material and exposed to the same analyte.
- Figure 4 shows a heating curve depicting the large main phase transition for unpolymerized liposomes prepared from PDA monomer.
- Figure 5 shows a schematic representation of a Langmuir Blodgett apparatus where a compressed film is being transferred to a vertical plate.
- Figure 6 shows a micrograph of liposomes cooled only to room temperature.
- Figure 7 shows a micrograph of liposomes prepared with cooling to 4°C.
- Figure 8 shows the chemical structure of 5,7-pentacosadiynoic acid.
- Figure 9 shows a synthesis reaction for modifying the free amino group of a molecule for coupling to a lipid monomer.
- Figure 10 shows the properties of biopolymeric materials composed of amino acid- derivated diacetylene monomers.
- Figure 1 1 shows the chemical structure of sialic acid derived 10,12- pentacosadiynoic acid (compound 1) and 10,12-pentacosadiynoic acid (compound 2).
- Figure 12 shows substrate lipid (i.e.. DMPC) in a diacetylenic lipid matrix before (top) and after (bottom) polymerization.
- substrate lipid i.e.. DMPC
- Figure 1 shows the visible absorption spectrum of the liposomes of Figure 12 before (solid line) and after (dashed line) exposure to phospholipase A,.
- Figure 14 shows the change in colorimetric response of the liposomes of Figure 12 with varying concentrations of DMPC in response to phospholipase A 2 exposure.
- Figure 15 shows the absorbance at 412 nm of liposomes containing l ,2-bis-(S- decanoyl)-1.2-dithio-sn-glycero-3-phosphocholine (DTPC) following exposure to PLA 2 for various lengths of time.
- Figure 16 shows j l P NMR spectra of the DMPC/PDA vesicles prior to the addition of PLA-, (A), and following the enzymatic reaction (B).
- Figure 17 shows the colorimetric response of DMPC containing liposomes in the presence of PLA : (circles), and PLA 2 with inhibitors (squares and diamonds).
- Figure 18 shows the visible absorption spectra of the polydiacetylene liposomes in a sol-gel matrix.
- Figure 19 shows the visible absorption spectra of the material in Figure 18 following heating of the liposomes to 55 °C.
- Figure 20 shows an optical micrograph of diacetylene film.
- Figure 21 shows the properties of polydiacetylene monolayers with and without sialic acid-deri ⁇ ated PDA and ganglioside G M1 .
- Figure 22 shows the isotherms of 5% G M 1 /5% SA-PDA/90% PDA as a function of subphase concentration of CdCl 2 .
- Figure 23 shows the isotherms of 5% G M I /5% SA-PDA/90% PDA at pH 4.5. 5.8. and 9.2.
- Figure 24 shows the temperature effect on the isotherms of 100%> PDA, 5%SA- PDA/95% PDA. and 5% G M I /5% SA-PDA/90% PDA.
- Figure 25 shows the visible absorption spectrum of "blue phase” 5% G M I and 95% 5.7-docosadiynoic acid liposomes.
- Figure 26 shows the visible absorption spectrum of the liposomes of Figure 25 following exposure to cholera toxin.
- Figure 27 shows the visible absorption spectrum for sialic-acid containing films before (solid line) and after (dashed line) exposure to influenza virus.
- Figure 28 shows the color transition of ganglioside G M ] -containing liposomes in response to varying concentrations of cholera toxin.
- Figure 29 shows the visible absorption spectrum of the polymeric liposomes containing 5% G M I ligand and 95% 5,7-DCDA.
- Figure 30 shows the visible absorption spectrum of the material in Figure 29 following exposure to E. coli toxin.
- Figure 31 shows the absorption spectrum of a PCA film in before (line a) and after exposure to 1 -octanol dissolved in water (line b).
- Figure 32 shows a bar graph indicating colorimetric responses of PDA material to various VOCs (Al and a table showing the concentration of the VOCs (B).
- Figure 33 shows a graph comparing colorimetric responses of biopolymeric material to 1-butanol to the concentration of 1-butanol.
- Figure 34 shows compounds and synthesis schematics for producing PDA derivatives for the detection of small organic compounds.
- Figure 36 shows the colorimetric response of hexokinase containing biopolymeric material to a variety of sugars.
- Figure 37 shows derivations of PDA for use in detection arrays.
- Figure 38 shows the organic synthesis of compound 2.10 from Figure 37.
- Figure 39 shows several embodiments of biopolymeric assemblies.
- Figures 40-50 show various embodiments of nucleic acid-coupled biopolymeric material generation and use. Each is described in more detail below.
- nucleic acid molecule refers to any nucleic acid containing molecule including, but not limited to DNA or RNA.
- the term encompasses sequences that include any of the known base analogs of DNA and RNA including, but not limited to. 4-acetylcytosine, 8-hydroxy-N6-methyladenosine. aziridinylcytosine, pseudoisocytosine. 5-(carboxyhydroxylmethyl) uracil, 5-fluorouracil, 5-bromouracil. 5- carboxymethylaminomethyl-2-thiouracil. 5-carboxymethylaminomethyluracil, dihydrouracil. inosine.
- N6-isopentenyladenine 1-methyladenine, 1 -methylpseudouracil, 1 -methylguanine.
- 1-methylinosine 2.2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methyl- cytosine.
- 5-methylcytosine. N6-methyladenine. 7-methylguanine, 5-methylaminomethyluracil. 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine.
- oligonucleotide refers to a short length of single- stranded polynucleotide chain. Oligonucleotides are typically less than 100 residues long (e.g.. between 15 and 50). however, as used herein, the term is also intended to encompass longer polynucleotide chains. Oligonucleotides are often referred to by their length. For example a 24 residue oligonucleotide is referred to as a "24-mer”. Oligonucleotides can form secondan- and tertiary structures by self-hybridizing or by hybridizing to other polynucleotides. Such structures can include, but are not limited to, duplexes, hairpins, cruciforms, bends, and triplexes.
- complementarity are used in reference to polynucleotides (i.e., a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence “A-G-T,” is complementary to the sequence “T-C- A.” Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions. as well as detection methods that depend upon binding between nucleic acids.
- the term "homology" refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity).
- a partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous.”
- the inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency.
- a substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous to a target under conditions of low stringency.
- low stringency conditions are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e.. selective) interaction.
- the absence of non-specific binding may be tested by the use of a second target that lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
- low stringency conditions factors such as the length and nature (DNA, RNA, base composition i of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g.. the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of low stringenc ⁇ hybridization different from, but equivalent to, the above listed conditions.
- conditions that promote hybridization under conditions of high stringency e.g., increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.
- substantially homologous refers to any probe that can hybridize to either or both strands of the double-stranded nucleic acid sequence under conditions of low stringency as described above.
- substantially homologous refers to any probe that can hybridize (i.e., it is the complement of) the single-stranded nucleic acid sequence under conditions of low stringency as described above.
- hybridization is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e.. the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, the T m of the formed hybrid, and the G:C ratio within the nucleic acids. A single molecule that contains pairing of complementary nucleic acids within its structure is said to be “self-hybridized.”
- T m is used in reference to the "melting temperature.”
- the melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands.
- PCR polymerase chain reaction
- the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule.
- the primers are extended with a polymerase so as to form a new pair of complementary strands.
- the steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one "cycle”; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence.
- the length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
- PCR polymerase chain reaction
- any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules.
- the amplified segments created by the PCR process are. themselves, efficient templates for subsequent PCR amplifications.
- PCR product refers to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation. annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.
- antisense is used in reference to DNA or RNA sequences that are complementary to a specific DNA or RNA sequence (e.g., mRNA). Included within this definition are antisense RNA (“asRNA”) molecules involved in gene regulation by bacteria. Antisense RNA may be produced by any method, including synthesis by splicing the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a coding strand. Once introduced into an embryo, this transcribed strand combines with natural mRNA produced by the embryo to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation. In this manner, mutant phenotypes may be generated.
- asRNA antisense RNA
- antisense strand is used in reference to a nucleic acid strand that is complementary to the "sense” strand.
- the designation (-) i.e. , "negative" is sometimes used in reference to the antisense strand, with the designation (+) sometimes used in reference to the sense (i.e.. "positive") strand.
- non-synthetic synthesis refers to the synthesis of biopolymeric materials, whereby one or more components of the assemly is not part of the polymer backbone.
- ganglioside is used as a ligand for the direct detection of analytes (e.g. , cholera toxin). where the ganglioside ligands are incorporated into the assemblies, but are not part of the polymerized network.
- reaction refers to any change or transformation in which a substance (e.g...
- reaction means refers to any means of initiating and/or catalyzing a reaction. Such reaction means include, but are not limited to. enzymes, temperature changes, and pH changes.
- affinity for said reaction means refers to compounds with the ability to specifically associate (e.g., bind) to a given reaction mean, although not necessarily a substrate for the reaction means.
- a PLA antibody has affinity for PLA 2 , but is not the substrate for the enzyme.
- immobilization refers to the attachment or entrapment, either chemical or otherwise, of material to another entity (e.g. , a solid support) in a manner that restricts the movement of the material.
- biopolymeric material refers to materials composed of polymerized biological molecules (e.g., lipids, proteins, carbohydrates, and combinations thereof). Such materials include, but are not limited to, films, vesicles, liposomes, multilayers, aggregates, membranes, and solvated polymers (e.g., polythiophene aggregates such as rods and coils in solvent).
- biopolymeric material comprises molecules that are not part of the polymerized matrix (i.e. , molecules that are not polymerized).
- protein is used in its broadest sense to refer to all molecules or molecular assemblies containing two or more amino acids. Such molecules include, but are not limited to, proteins, peptides, enzymes, antibodies, receptors, lipoproteins, and glycoproteins.
- antibody refers to a glycoprotein evoked in an animal by an immunogen ( antigen).
- An antibody demonstrates specificity to the immunogen, or, more specifically . to one or more epitopes contained in the immunogen.
- Native antibody comprises at least two light polypeptide chains and at least two heavy polypeptide chains. Each of the and light polypeptide chains contains at the amino terminal portion of the polypeptide chain a variable region (i.e.. VH and VL respectively), which contains a binding domain that interacts with antigen.
- Each of the heavy and light polypeptide chains also comprises a constant region of the polypeptide chains (generally the carboxy terminal portion) which may mediate the binding of the immunoglobulin to host tissues or factors influencing various cells of the immune system, some phagocytic cells and the first component (Clq) of the classical complement system.
- the constant region of the light chains is referred to as the "CL region,” and the constant region of the heavy chain is referred to as the "CH region.”
- the constant region of the heavy chain comprises a CHI region, a CH2 region, and a CH3 region. A portion of the heavy chain between the CHI and CH2 regions is referred to as the hinge region (i.e. , the "H region").
- the constant region of the chain of the cell surface form of an antibody further comprises a spacer-transmembranal region (Ml) and a cytoplasmic region (M2) of the membrane carboxy terminus.
- the secreted form of an antibody generally lacks the Ml and M2 regions.
- biopolymeric films refers to polymerized organic films that are used in a thin section or in a layer form. Such films can include, but are not limited to, monolayers, bilayers, and multilayers. Biopolymeric films mimic biological cell membranes (e.g. , in their ability to interact with other molecules such as proteins or analytes).
- sol-gel refers to preparations composed of porous metal oxide glass structures. Such structures can have biological or other material entrapped within the porous structures.
- sol-gel matrices refers to the structures comprising the porous metal oxide glass with or without entrapped material.
- sol-gel material refers to any material prepared by the sol-gel process including the glass material itself and any entrapped material within the porous structure of the glass.
- sol-gel method refers to any method that results in the production of porous metal oxide glass. In some embodiments, “sol-gel method” refers to such methods conducted under mild temperature conditions.
- sol-gel glass and metal oxide glass refer to glass material prepared by the sol-gel method and include inorganic material or mixed organic/inorganic material. The materials used to produce the glass can include, but are not limited to. aluminates. aluminosilicates, titanates, ormosils (organically modified silanes), and other metal oxides.
- direct colorimetric detection refers to the detection of color changes without the aid of an intervening processing step (e.g., conversion of a color change into an electronic signal that is processed by an interpreting device). It is intended that the term encompass visual observing (e.g., observing with the human eye) as well as detection by simple spectrometry.
- analytes refers to any material that is to be analyzed.
- Such materials include, but are not limited to, ions, molecules, antigens, bacteria, compounds, viruses, cells, antibodies, and cell parts.
- selective binding refers to the binding of one material to another in a manner dependent upon the presence of a particular molecular structure (i.e.. specific binding).
- a receptor will selectively bind ligands that contain the chemical structures complementary to the ligand binding site(s). This is in contrast to "non-selective binding,” whereby interactions are arbitrary and not based on structural compatibilities of the molecules.
- biosensors refers to any sensor device that is partially or entirely composed of biological molecules.
- the term refers to "an analytical tool or system consisting of an immobilized biological material (such as enzyme. antibod ⁇ '. whole cell, organelle, or combination thereof) in intimate contact with a suitable transducer device which will convert the biochemical signal into a quantifiable electrical signal” (Gronow. Trends Biochem. Sci. 9: 336 [1984]).
- the term "transducer device” refers to a device that is capable of converting a non-electrical phenomenon into electrical information, and transmitting the information to a device that interprets the electrical signal.
- Such devices include, but are not limited to, devices that use photometry, fluorimetry, and chemiluminescence; fiber optics and direct optical sensing (e.g., grating coupler); surface plasmon resonance; potentiometric and amperometric electrodes; field effect transistors; piezoelectric sensing: and surface acoustic wave.
- miniaturization refers to a reduction in size, such as the size of a sample to increase utility (e.g., portability, ease of handling, and ease of incorporation into arrays).
- the term “stability” refers to the ability of a material to withstand deterioration or displacement and to provide reliability and dependability.
- the term “conformational change” refers to the alteration of the molecular structure of a substance. It is intended that the term encompass the alteration of the structure of a single molecule or molecular aggregate (e.g., the change in structure of polydiacetylene upon interaction with an analyte).
- the term “small molecules” refers to any molecule with low molecular weight (i.e.
- pathogen refers to disease causing organisms, microorganisms, or agents including, but not limited to. viruses, bacteria, parasites (including, but not limited to, organisms within the phyla Protozoa, Platyhelminthes, Aschelminithes. Acanthocephala, and Arthropoda), fungi, and prions.
- bacteria and "bacterium” refer to all prokaryotic organisms, including those within all of the phyla in the Kingdom Procaryotae. It is intended that the term encompass all microorganisms considered to be bacteria including Mycoplasma, Chlamydia, Actinomyces, Streptomyces, and Rickettsia. All forms of bacteria are included within this definition including cocci, bacilli, spirochetes, spheroplasts. protoplasts, etc. "Gram negative” and "gram positive” refer to staining patterns obtained with the Gram-staining process which is well known in the art (See e.g., Finegold and Martin. Diagnostic Microbiology, 6th Ed. (1982), CV Mosby St. Louis, pp 13-15).
- membrane refers to, in its broadest sense, a sheet or layer of material. It is intended that the term encompass all "biomembranes” (i.e. , any organic membrane including, but not limited to, plasma membranes, nuclear membranes, organelle membranes, and synthetic membranes). Typically, membranes are composed of lipids. proteins, glycolipids, steroids, sterols and/or other components. As used herein, the term “membrane fragment” refers to any portion or piece of a membrane. The term “polymerized membrane” refers to membranes that have undergone partial or complete polymerization.
- membrane rearrangement and “membrane conformational change” refer to any alteration in the structure of a membrane. Such alterations can be caused by physical perturbation, heating, enzymatic and chemical reactions, among other events. Reactions that can result in membrane rearrangement include, but are not limited to lipid cleavage, polymerization, lipid flipping, transmembrane signalling, vesicle formation, lipidation, glycosylation, ion channeling, molecular rearrangement, and phosphorylation. Enzymatic catalysis that results in membrane rearrangement can result from free enzymes interacting with the biopolymeric material (e.g.. reacting with an enzyme substrate in the biopolymeric material) and can result from enzymatic activity present in certain analytes (e.g. , viruses, bacteria, and toxins among others).
- analytes e.g. , viruses, bacteria, and toxins among others.
- lipid cleavage refers to any reaction that results in the division of a lipid or lipid-comprising material into two or more portions.
- “Lipid cleavage means” refers to any means of initiating and/or catalyzing lipid cleavage. Such lipid cleavage means include, but are not limited to enzymes, free radical reactions, and temperature changes.
- polymerization encompasses any process that results in the conversion of small molecular monomers into larger molecules consisting of repeated units. Typically, polymerization involves chemical crosslinking of monomers to one another.
- membrane receptors refers to constituents of membranes that are capable of interacting with other molecules or materials. Such constituents can include, but are not limited to, proteins, lipids, carbohydrates, and combinations thereof.
- volatile organic compound or “VOC” refers to organic compounds that are reactive (i.e., evaporate quickly, explosive, corrosive, etc.), and typically are hazardous to human health or the environment above certain concentrations.
- VOCs include, but are not limited to, alcohols, benzenes, toluenes, chloroforms, and cyclohexanes.
- enzyme refers to molecules or molecule aggregates that are responsible for catalyzing chemical and biological reactions. Such molecules are typically proteins, but can also comprise short peptides, RNAs, ribozymes, antibodies, and other molecules.
- reaction substrate refers to the substrate for a reaction means (e.g. , a "substrate lipid” reacted by a lipid cleavage means).
- analyte substrate refers to a material or substance upon which an analyte reacts.
- the analyte can be an enzyme and the analyte substrate is an enzyme substrate.
- the analyte can be a pathogen and the analyte substrate comprises a material or sample that is altered by a "reaction means” associated with the pathogen.
- lipase refers to any of a group of hydrolytic enzymes that acts on ester bonds in lipids.
- Upases include, but are not limited to, pancreatic lipase that catalyses the hydrolysis of triacylglycerols, lipoprotein lipase that catalyzes the hydrolysis of triacylglycerols to glycerol and free fatty acids, and phospholipases, among others.
- the term "phospholipase” refers to enzymes that cleave phospholipids by the hydrolysis of carbon-oxygen or phosphorus-oxygen bonds.
- Phospholipases include, but are not limited to, phospholipases A,, A 2 , C, and D.
- drug refers to a substance or substances that are used to diagnose, treat, or prevent diseases or conditions. Drugs act by altering the physiology of a living organism, tissue, cell, or in vitro system that they are exposed to. It is intended that the term encompass antimicrobials, including, but not limited to, antibacterial, antifungal. and antiviral compounds. It is also intended that the term encompass antibiotics, including naturally occurring, synthetic, and compounds produced by recombinant DNA technology. As used herein, the term “peptide” refers to any substance composed of two or more amino acids.
- carbohydrate refers to a class of molecules including, but not limited to. sugars, starches, cellulose, chitin, glycogen, and similar structures. Carbohydrates can also exist as components of glycolipids and glycoproteins.
- chromophore refers to molecules or molecular groups responsible for the color of a compound, material, or sample.
- an antigen refers to any molecule or molecular group that is recognized by at least one antibody.
- an antigen must contain at least one epitope (i.e.. the specific biochemical unit capable of being recognized by the antibody).
- immunogen refers to any molecule, compound, or aggregate that induces the production of antibodies.
- an immunogen must contain at least one epitope (i.e. , the specific biochemical unit capable of causing an immune response).
- chelating compound refers to any compound composed of or containing coordinate links that complete a closed ring structure.
- the compounds can combine with metal ions, attached by coordinate bonds to at least two of the nonmetal ions.
- molecular recognition complex refers to any molecule, molecular group, or molecular complex that is capable of recognizing (i.e., specifically interacting with) a molecule.
- the ligand binding site of a receptor would be considered a molecular recognition complex.
- ambient condition refers to the conditions of the surrounding environment (e.g. , the temperature of the room or outdoor environment in which an experiment occurs).
- room temperature refers, technically, to temperatures approximately between 20 and 25 degrees centigrade. However, as used generally, it refers to the am ambient temperature within a general area in which an experiment is taking place.
- home testing and “point of care testing” refer to testing that occurs outside of a laboratory environment. Such testing can occur indoors or outdoors at. for example, a private residence, a place of business, public or private land, in a vehicle, under water, as well as at the patient ' s bedside.
- lipid refers to a variety of compounds that are characterized b ⁇ their solubility in organic solvents. Such compounds include, but are not limited to. fats, waxes, steroids, sterols, glycolipids, glycosphingolipids (including gangliosides). phospholipids, terpenes, fat-soluble vitamins, prostaglandins, carotenes, and chlorophylls.
- lipid-based materials refers to any material that contains lipids.
- virus refers to minute infectious agents, which with certain exceptions, are not observable by light microscopy, lack independent metabolism, and are able to replicate only within a living host cell.
- the individual particles consist of nucleic acid and a protein shell or coat; some virions also have a lipid containing membrane.
- the term "virus” encompasses all types of viruses, including animal, plant, phage, and other viruses.
- free floating aggregates refers to aggregates that are not immobilized.
- encapsulate refers to the process of encompassing, encasing, or otherwise associating two or more materials such that the encapsulated material is immobilized within or onto the encapsulating material.
- optical transparency refers to the property of matter whereb) the matter is capable of transmitting light such that the light can be observed b> visual light detectors (e.g . eyes and detection equipment).
- biologically inert refers to a property of material whereby the material does not chemically react with biological material.
- organic solvents refers to any organic molecules capable of dissolving another substance. Examples include, but are not limited to, chloroform, alcohols, phenols, and ethers.
- nanostructures refers to microscopic structures, typically measured on a nanometer scale. Such structures include various three-dimensional assemblies, including, but not limited to, liposomes, films, multilayers, braided, lamellar, helical, tubular, and fiber-like shapes, and combinations thereof. Such structures can. in some embodiments, exist as solvated polymers in aggregate forms such as rods and coils.
- films refers to any material deposited or used in a thin section or in a er form.
- vesicle refers to a small enclosed structures. Often the structures are membranes composed of lipids, proteins, glycolipids. steroids or other components associated with membranes. Vesicles can be naturally generated (e.g.. the vesicles present in the cytoplasm of cells that transport molecules and partition specific cellular functions) or can be synthetic (e.g., liposomes).
- liposome refers to artificially produced spherical lipid complexes that can be induced to segregate out of aqueous media.
- liposome and vesicle are used interchangeably herein.
- biopolymeric liposomes refers to liposomes that are composed entire . or in part, of biopolymeric material.
- tubules refers to materials comprising small hollow cylindrical structures.
- solvated polymer solvated rod
- solvated coil refer to polymerized materials that are soluble in aqueous solution.
- multilayer refers to structures comprised of two or more monolayers.
- the individual monolayers may chemically interact with one another (e.g.. through covalent bonding, ionic interactions, van der Waals " interactions, hydrogen bonding, hydrophobic or hydrophilic assembly, and stearic hindrance) to produce a film with novel properties (i. e.. properties that are different from those of the monolayers alone).
- self-assembling monomers and “lipid monomers” refer to molecules that spontaneously associate to form molecular assemblies. In one sense, this can refer to surfactant molecules that associate to form surfactant molecular assemblies.
- self-assembling monomers includes single molecules (e.g...
- Small molecular assemblies refers to an assembly of surface active agents that contain chemical groups with opposite polarity, form oriented monolayers at phase interfaces, form micelles (colloidal particles in aggregation colloids), and have detergent, foaming, wetting, emulsifying, and dispersing properties.
- the term “homopolymers” refers to materials comprised of a single type of polymerized molecular species.
- mixtureed polymers refers to materials comprised of two or more types of polymerize molecular species.
- ligands refers to any ion, molecule, molecular group, or other substance that binds to another entity to form a larger complex. Examples of ligands include, but are not limited to, peptides, carbohydrates, nucleic acids (e.g. , DNA and RNA). antibodies, or any molecules that bind to receptors.
- dopant refers to molecules that are added to biopolymeric materials to change the material ' s properties. Such properties include, but are not limited to. colorimetric response, color, sensitivity, durability, robustness, amenability to immobilization, temperature sensitivity, and pH sensitivity.
- Dopant materials include, but are not limited to, lipids. cholesterols, steroids, ergosterols, polyethylene glycols, proteins, peptides, or any other molecule (e.g.. surfactants, polysorbate. octoxynol, sodium dodecyl sulfate, zwitterionic detergents, decylglucoside.
- deoxycholate diacetylene derivatives, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine.
- phosphatidylcholine phosphatidylglycerol.
- phosphatidic acid phosphatidylmethanol, cardiolipin. ceramide. cerebroside, lysophosphatidylcholine, D- erythroshingosine.
- sphingomyelin dodecyl phosphocholme, N-biotinyl phosphatidylethanolamine. and other synthetic or natural components of cell membranes) that can be associated with a membrane (e.g.. liposomes and films).
- organic matrix and “biological matrix” refer to collections of organic molecules that are assembled into a larger multi-molecular structure. Such structures can include, but are not limited to, films, monolayers, and bilayers.
- organic monolayer refers to a thin film comprised of a single layer of carbon-based molecules. In one embodiment, such monolayers can be comprised of polar molecules whereby the hydrophobic ends all line up at one side of the monolayer.
- monolayer assemblies refers to structures comprised of monolayers.
- organic polymetric matrix refers to organic matrices whereby some or all of the molecular constituents of the matrix are polymerized.
- head group and “head group functionality” refer to the molecular groups present an the ends of molecules (e.g. , the carboxylic acid group at the end of fatty acids).
- hydrophilic head-group refers to ends of molecules that are substantially attracted to water by chemical interactions including, but not limited to. hydrogen-bonding, van der Waals " forces, ionic interactions, or covalent bonds.
- hydrophobic head-group refers to ends of molecules that self-associate with other hydrophobic entities, resulting in their exclusion from water.
- carboxylic acid head groups refers to organic compounds containing one or more carboxyl (-COOH) groups located at, or near, the end of a molecule.
- carboxylic acid includes carboxyl groups that are either free or exist as salts or esters.
- detecting head group refers to the molecular group contained at the end of a molecule that is involved in detecting a moiety (e.g. , an analyte).
- linker or "spacer molecule” refers to material that links one entity to another. In one sense, a molecule or molecular group can be a linker that is covalent attached two or more other molecules (e.g. , linking a ligand to a self-assembling monomer).
- polymeric assembly surface refers to polymeric material that provides a surface for the assembly of further material (e.g.. a biopolymeric surface of a film or liposome that provides a surface for attachment and assembly of ligands).
- formation support refers to any device or structure that provides a physical support for the production of material. In some embodiments, the formation support provides a structure for layering and/or compressing films.
- diacetylene monomers refers to single copies of hydrocarbons containing two alkyne linkages (i.e.. carbon/carbon triple bonds).
- standard trough and “standard Langmuir-Blodgett trough” refer to a device, usually made of teflon, that is used to produce Langmuir films.
- the device contains a reservoir that holds an aqueous solution and moveable barriers to compress film material that are layered onto the aqueous solution (See e.g. , Roberts. Langmuir-Blodgett Films, Plenum, New York. [1990]).
- crystalline morphology refers to the configuration and structure of c ⁇ stals that can include, but are not limited to, crystal shape, orientation. texture, and size.
- domain boundary refers to the boundaries of an area in which polymerized film molecules are homogeneously oriented.
- a domain boundary can be the physical structure of periodic, regularly arranged polydiacetylene material (e.g.. striations, ridges, and grooves).
- domain size refers to the typical length between domain boundaries.
- conjugated backbone and “polymer backbone” refer to the ene- yne polymer backbone of polymerized diacetylenic films that, on a macroscopic scale, appears in the form of physical ridges or striations.
- polymer backbone axis refers to an imaginary line that runs parallel to the conjugated backbone.
- intrabackbone and interbackbone refer to the regions within a given polymer backbone and between polymer backbones, respectiveh .
- the backbones create a series of lines or “linear striations.” that extend for distances along the template surface.
- bond refers to the linkage between atoms in molecules and between ions and molecules in crystals.
- single bond refers to a bond with two electrons occupying the bonding orbital. Single bonds between atoms in molecular notations are represented by a single line drawn between two atoms (e.g.. C 8 -C 9 ).
- double bond refers to a bond that shares two electron pairs. Double bonds are stronger than single bonds and are more reactive.
- triple bond refers to the sharing of three electron pairs.
- ene-yne refers to alternating double and triple bonds.
- amine bond As used herein the terms “amine bond.” “thiol bond,” and “aldehyde bond” refer to any bond formed between an amine group (i.e. , a chemical group derived from ammonia by replacement of one or more of its hydrogen atoms by hydrocarbon groups), a thiol group (i.e., sulfur analogs of alcohols), and an aldehyde group (i.e. , the chemical group -CHO joined directly onto another carbon atom), respectively, and another atom or molecule.
- amine group i.e. , a chemical group derived from ammonia by replacement of one or more of its hydrogen atoms by hydrocarbon groups
- a thiol group i.e., sulfur analogs of alcohols
- aldehyde group i.e. , the chemical group -CHO joined directly onto another carbon atom
- covalent bond refers to the linkage of two atoms by the sharing of two electrons, one contributed by each of the atoms.
- the term “absorption” refers, in one sense, to the absorption of light. Light is absorbed if it is not reflected from or transmitted through a sample. Samples that appear colored have selectively absorbed all wavelengths of white light except for those corresponding to the visible colors that are seen.
- the term “spectrum” refers to the distribution of light energies arranged in order of wavelength.
- visible spectrum refers to light radiation that contains wavelengths from approximately 360 nm to approximately 800 nm.
- ultraviolet irradiation refers to exposure to radiation with wavelengths less than that of visible light (i.e., less than approximately 360 nM) but greater than that of X-rays (i.e., greater than approximately 0.1 nM). Ultraviolet radiation possesses greater energy than visible light and is therefore, more effective at inducing photochemical reactions.
- chromatic transition refers to the changes of molecules or material that result in an alteration of visible light absorption.
- chromatic transition refers to the change in light absorption of a sample, whereby there is a detectable color change associated with the transition. This detection can be accomplished through various means including, but not limited to, visual observation and spectrophotomet ⁇ .
- thermal transition refers to a chromatic transition that is initiated b ⁇ a change in temperature.
- solid support refers to a solid object or surface upon which a sample is layered or attached.
- Solid supports include, but are not limited to, glass, metals, gels, and filter paper, among others.
- Hydrodrophobized solid support refers to a solid support that has been chemically treated or generated so that it attracts hydrophobic entities and repels water.
- film-ambient interface refers to a film surface exposed to the ambient environment or atmosphere (/. e. , not the surface that is in contact with a solid support).
- formation solvent refers to any medium, although typically a volatile organic solvent, used to solubilize and distribute material to a desired location (e.g. , to a surface for producing a film or to a drying receptacle to deposit liposome material for drying).
- the term “micelle” refers to a particle of colloidal size that has a hydrophilic exterior and hydrophobic interior.
- topochemical reaction refers to reactions that occur within a specific place (e.g.. within a specific portion of a molecule or a reaction that only occurs when a certain molecular configuration is present).
- the term “molding structure” refers to a solid support used as a template to design material into desired shapes and sizes.
- array and “patterned array” refer to an arrangement of elements (i.e., entities) into a material or device. For example, combining several types of biopolymeric material with different analyte recognition groups into an analyte-detecting device, would constitute an array.
- interferants refers to entities present in an analyte sample that are not the analyte to be detected and that, preferably, a detection device will not identify, or would differentiate from the analyte(s) of interest.
- the term "badge” refers to any device that is portable and can be carried or worn by an individual working in an analyte detecting environment.
- the term "device” refers to any apparatus (e.g. , multi-well plates and badges) that contain biopolymeric material.
- the biopolymeric material may be immobilized or entrapped in the device. More than one type of biopolymeric material can be incorporated into a single device.
- halogenation refers to the process of incorporating or the degree of incorporation of halogens (i.e., the elements fluorine, chlorine, bromine. iodine and astatine) into a molecule.
- aromaticity refers to the presence of aromatic groups (i.e.. six carbon rings and derivatives thereof) in a molecule.
- water-immiscible solvents refers to solvents that do not dissolve in water in all proportions.
- water-miscible solvents refers to solvents that dissolve in water in all proportions.
- the terms "positive.” “negative,” and “zwitterionic charge” refer to molecules or molecular groups that contain a net positive, negative, or neutral charge, respectively. Zwitterionic entities contain both positively and negatively charged atoms or groups whose charges cancel (i.e., whose net charge is 0).
- biological organisms refers to any carbon-based life forms.
- in situ refers to processes, events, objects, or information that are present or take place within the context of their natural environment.
- aqueous refers to a liquid mixture containing water, among other components.
- solid-state refers to reactions involving one or more rigid or solid-like compounds.
- the term “regularly packed” refers to the periodic arrangement of molecules within a compressed film.
- filtration refers to the process of separating various constituents within a test sample from one another.
- filtration refers to the separation of solids from liquids or gasses by the use of a membrane or medium.
- the term encompasses the separation of materials based on their relative size.
- inhibitor refers to a material, sample, or substance that retards or stops a chemical reaction.
- reaction means inhibitor refers to inhibitors that are capable of retarding or stopping the action or activity of a given reaction means (e.g. , an enzyme).
- inhibitor screening refers to any method used to identify and/or characterize inhibitors.
- inhibitor screening methods provide "high throughput screening.” the ability to screen a large number of samples suspected of containing inliibitors in a short period of time. It may also be desired that the inhibitor screening method provide quantifiable results to provide comparisons of inhibitor efficiencv.
- sample is used in its broadest sense. In one sense it can refer to a biopolymeric material. In another sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like. Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.
- the present invention relates to methods and compositions for the direct detection of membrane conformational changes through the detection of color changes in biopolymeric materials.
- the polydiacetylene sensors composed of fully conjugated polymer backbones embedded in lipid bilayers, undergo colorimetric transitions upon a specific binding event between a surface bound ligand and a receptor or host molecule in the sample specimen.
- the chromophoric detection unit is built into the sensor and can be visually monitored by the naked eye, making any further detection procedures unnecessary.
- attachment of synthetic oligodeoxynucleotides to such sensor surfaces provides devices that allow direct detection of nucleic acid hybridization events by colorimetric transition.
- ligands that allow direct colorimetric detection of nucleic acid hybridization are incorporated into polymerized biosensors.
- the present invention provides methods and compositions related to the specific detection of nucleic acid hybridization via recognition of a single stranded sample nucleic acid with a single stranded probe nucleic acid, which is covalently attached to the surface of the biopolymeric material of the present invention.
- a visible transition from blue to the red form of the biopolymeric material allows specific detection of nucleic acid hybridization.
- This colorimetric response upon nucleic acid hydribidization provides a quick and simple detection of specific nucleic acid fragments (e.g. , produced by the PCR) or as a diagnostic tool in medicine.
- the nucleic acid-linked biopolymeric material provides a means to detect the presence and activity of enzymes or other molecule that associate with or alter nucleic acid samples.
- the present invention provide compositions and methods related to the construction, characterization and optimization of patterned nucleic acid sensors based on the photochromic transition in biopolymeric materials upon nucleic acid hybridization.
- an array of patterned nucleic acid assays are incorporated into a single device, such that parallel detection of many different hybridization events occurs simultaneously.
- Such arrays are designed so that the presence of a given analyte produces a color change in a known location in the device, or that produces a color change specific to the given analyte (e.g. , purple to orange for analyte 1 and blue to red for analyte 2). It is also contemplated that other arrays are used with the present invention, including such easily understood patterns as a "+" sign to indicate that presence of a particular substance or compound. It is not intended that the present invention be limited to any particular array design or configuration.
- the present invention comprises methods and compositions related to biopolymeric materials that change color in response to membrane rearrangements through ligand analyte binding or other rearrangements.
- biopolymeric materials comprise many forms including, but not limited to, films, vesicles, tubules, multilayered structures, and solvated rods and coils.
- These biopolymeric materials are comprise polymerized self- assembling monomers.
- the biopolymeric materials comprise more than one species of self-assembling monomer. Some of these self-assembling monomers may lack polymerizable groups.
- the materials further comprise dopant material(s) that alter the properties of the sensor.
- Dopants include, but are not limited to, polymerizable self-assembling monomers, non-polymerizable self-assembling monomers, lipids. sterols, membrane components, and any other molecule that optimizes the biopolymeric material (e.g., material stability, durability, colorimetric response, and immobilizability).
- the biopolymeric material may further comprise ligands (e.g. , proteins, antibodies, carbohydrates, and nucleic acids). The ligands provide attachment sites for recruiting molecules to the biopolymeric surface or are used as binding sites for analytes. whereby the binding event causes a colorimetric change in the biopolymeric material.
- the various embodiments of the present invention provide the ability to colorimetrically detect a broad range reactions and analytes. With certain biopolymeric materials, a color transition in response to a reaction is viewed by simple visual observation or, if desired, by color sensing equipment.
- the present invention further provides a variety of means of immobilizing the biopolymeric material to provide stability, durability, and ease of handling and use.
- a variety of different polymeric materials are combined into a single device to produce an array.
- the array is designed to detect and differentiate differing types or quantities of reactions or analytes (i.e., the array can provide quantitative and/or qualitative data).
- biopolymeric materials described in these sections can be designed to detect the presence of analytes (e.g., pathogens, chemicals, nucleic acids, and proteins) and can be designed to detect membrane rearrangements (e.g., lipid cleavage events and modification of nucleic acids). In some embodiments, it may be desired to have biopolymeric materials that accomplish both of these functions.
- analytes e.g., pathogens, chemicals, nucleic acids, and proteins
- membrane rearrangements e.g., lipid cleavage events and modification of nucleic acids.
- the optimization of the biopolymeric materials e.g. , optimization of colorimetric response, color, and stability
- the biopolymeric material of the presently invention can take many physical forms including, but not limited to. liposomes, films, and multilayers, as well as braided, lamellar, helical, tubular, and fiber-like shapes, and combinations thereof.
- the biopolymeric materials are solvated polymers in aggregate forms such as rods and coils. Each of these classes is described below, highlighting their advantages and the difficulties ercome during the development of these materials.
- the biopolymeric material used in the present invention comprise biopolymeric film.
- biopolymeric films were prepared by layering the desired matrix-forming material (e.g.. self-assembling organic monomers) onto a formation support.
- the formation support was a standard Langmuir-Blodgett trough and the matrix-forming material was layered onto an aqueous surface created by filling the trough with an aqueous solution. The material was then compressed and polymerized to form a biopolymeric film.
- the compression was conducted in a standard Langmuir-Blodgett trough using moveable barriers to compress the matrix-forming material. Compression was carried out until a tight-packed monolayer of the matrix-forming material was formed. Films provide a very sensitive colorimetric screen for analytes.
- the matrix-forming material located within the formation support, was polymerized by ultra-violet irradiation.
- ultra-violet irradiation all methods of polymerization are contemplated by the present invention and include, but are not limited to, gamma irradiation, x-ray irradiation, chemical crosslinking. and electron beam exposure.
- lipids comprising diacetylene monomers were used as the self-assembling monomer.
- the diacetylene monomers (DA) were polymerized to polydiacetylene (p-PDA or PDA) using ultraviolet irradiation.
- the ultraviolet radiation source is kept sufficiently far from the film to avoid causing heat damage to the film.
- the crystalline morphology of the polymerized film can be readily observed between crossed polarizers in an optical microscope, although this step is not required by the present invention.
- the conjugated backbone of alternating double and triple bonds i.e.. ene-yne
- the visibly blue films were then transferred to hydrophobized solid supports, such that the carboxylic acid head groups were exposed at the film-ambient interface (Charych et al. Science 261 : 585 [1993]) to undergo further analysis, although the method of the present invention does not require this step.
- Linear striations typical of PDA films can be observed in the polarizing optical microscope.
- the material may also be characterized using atomic force microscopy or other characterization means (See e.g.. Example 2).
- films can be made by solvent casing (i.e.. slow evaporation of the solvent).
- lipid monomers can be made with silane or thiol anchoring groups, which allows dipping of solid supports into the solution to form a coated solid support.
- diacetylene monomers are anchored by the silane and thiol groups and are then polymerized. This method eliminates the need for a trough.
- the biopolymeric material used in the present invention comprises biopolymeric liposomes.
- Liposomes were prepared using a probe sonication method (New. Liposomes: A Practical Approach. Oxford University Press, Oxford, pp 33-104 [1990]). although any method that generates liposomes is contemplated by the present invention.
- Self-assembling monomers either alone, or associated with a desired ligand. were dried to remove the formation solvents and resuspended in deionized water. The suspension was probe sonicated and polymerized. The resulting liposome solution contained biopolymeric liposomes.
- Liposomes differ from monolayers and films in both their physical characteristics and in the methods required to generate them.
- Monolayers and films (or multilayers) made from amphiphilic compounds are planar membranes and form a two-dimensional architecture.
- Monolayers and films, in this context, are solid state materials that are supported by an underlying solid substrate as shown in Figure 1.
- Film Y is a centrosymmetric multilayer film
- films X and Z are noncentrosymmetric multilayers.
- Ulman Ulman. An Introduction to Ultrathin Organic Films: From Langmuir-Blodgett to Self -Assembly.
- liposomes are three-dimensional vesicles that enclose an aqueous space as shown in Figure 2.
- Figure 2 shows A) a cross-section two-dimensional view; and B) a three-dimensional view of half of a liposome.
- Liposomes can be constructed so that they entrap materials within their aqueous compartments. Films and monolayers do not enclose an aqueous space and do not entrap materials within a compartment. The liposomes are typically more stable and robust than the films made of the same material.
- Liposomes and films are prepared using different methods. Liposomes are prepared by dispersal of amphiphilic molecules in an aqueous media and remain in the liquid phase. In contrast, monolayers and films are prepared by immobilizing amphiphilic molecules at the air- water interface. A solid support is then passed through the interface to transfer the film to the solid support. Liposomes exist within homogenous aqueous suspensions and may be created in a variety of shapes such as spheres, ellipsoids, squares, rectangles, and tubules. Thus, the surface of a liposome is in contact with liquid only— primarily water. In some respects, liposomes resemble the three-dimensional architecture of natural cell membranes.
- liposomes are dried to their solid state, they may lose their shape and no longer exist in a liposomal state (i.e. , are no longer "liposomes").
- films exist as planar heterogeneous coatings, immobilized onto a solid support. The surface of a monolayer or film can be in contact with air. other gases, or other liquids. Films can be dried in air and maintain their planar monolayer or multilayer structure and thus remain as "films.”
- Liposomes have the advantage, generally, of making the color change more visually striking and increasing the colorimetric response (See e.g.. Figure 3 showing the colorimetric response of immobilized sialic-acid-containing liposomes (1) and films (2) to the presence of influenza virus).
- polymerization requires that the lipids pack in a precise distance and orientation with respect to one another.
- the polymerization of polydiacetylene is therefore a "solid state” or topochemical polymerization. This is why the molecules must be closely packed to allow cross-linking. This precise packing can be controlled in monolayer and films at the air-water interface using moveable barriers of
- the conjugated polymer backbone that provides the liposomes with the desired color, and potentially allows the detection of biological analytes through an observable color change produced by the binding of the analyte to the liposomes.
- the liposomes were formed (i.e. , using the methods described above) and cooled to room temperature, it was found that they did not polymerize at all upon exposure to ultraviolet light. This was surprising because, in principle, the lipids should have crystallized and returned to their solid-like state when cooled to room temperature (i.e.. once the lipids returned to this state, they should have undergone the topochemical polymerization as described above). However, they did not, as apparently the lipids were still fluid.
- nanostructures include, but are not limited to, multilayers, braided, lamellar, helical, tubular, and fiber-like shapes, and combinations thereof.
- Such structures can. in some embodiments, be solvated polymers in aggregate forms such as rods and coils. For example, it has been shown that the chain length of the monomers effects the type of aggregate that forms in solution (Okahata and Kunitake, J. Am. Chem. Soc. 101 : 5231 [1979]).
- bilayer systems of polydiacetylene lipids can be prepared to serve as colorimetric detectors.
- Such structures include molecular double layers on solid supports created by LB. Langmuir-Schaefer transfer, or by adsorption and unrolling of monomeric liposomes. followed by photopolymerization ( Figure 39[I]).
- a related system is the tethered supported bilayer ( Figure 39[II]) with a ' cushion' layer sandwiched between the substrate surface and the bilayer. This 'cushion' layer decouples the flexible bilayer from the immobile solid support and allows, for example, incorporation of membrane proteins.
- a third structural variation is the covalent fixation of polymeric liposomes at planar surfaces of self-assembled monolayers ( Figure 39[III]).
- soluble polymers of polythiophenes are generated.
- sugar groups, peptides, or other ligands can be synthesized as thiophene derivatives and then polymerized as co-polymers.
- NHS derivatives of thiophene can be polymerized and ligand groups can be attached after the polymer has formed (described below).
- the thiophene polymers are rendered water soluble by the addition of acid groups. Thus they are synthesized to freely dissolve in aqueous solution, creating a colorimetric solution.
- the present invention contemplates a variety of self-assembling monomers that are suitable for formation of biopolymeric materials.
- Such monomers include, but are not limited to. acetylenes, diacetylenes (e.g.. 5,7-docosadiynoic acid. 5.7-pentacosadiynoic acid, and 10,12-pentacosadiynoic acid), alkenes. thiophenes. polythiophenes. imides, acrylamides, methacrylates, vinylether. malic anhydride, urethanes.
- allylamines siloxanes, poly-silanes, anilines, pyrroles, polyacetylenes, poly (para- phylenevinylene). poly (para-phylene), and vinylpyridinium. Lipids containing these groups can be homopolymers or mixed polymers. Furthermore, monomers with a variety of head groups are contemplated, including, but not limited to carboxylic acid, hydroxyl groups, primary amine functionalities, amino acid derivatives, and hydrophobic groups. Certain head groups may act as recognition sites for binding to analytes, allowing direct colorimetric detection, simply through exposure of the biopolymeric material to the analyte.
- the biopolymeric material of the present invention may comprise a single species of self-assembling monomer (e.g., may be made entirely of 5.7-pentacosadiynoic acid) or may comprise two or more species.
- solvents containing the individual monomers are combined in the desired molar ratio. This mixture is then prepared as described above (e.g.. layering onto the aqueous surface of a Langmuir-Blodgett device for film preparation or evaporated and resuspended in aqueous solution for liposome preparation).
- the self-assembling monomers may be chemically linked to another molecule (e.g.. a ligand).
- lipid monomers comprising diacetylene were used as the self-assembling monomers of the biopolymeric material of the present invention.
- the present invention contemplates a variety of diacetylene-containing lipids including, but not limited to 5,7-docosadiynoic acid (5,7-DCDA), 5,7-pentacosadiynoic acid (5,7-PCA). and 10,12-pentacosadiynoic acid (10,12-PCA).
- the present invention further contemplates the optimization of the biopolymeric material to maximize response to given reaction conditions.
- the chemistry of the particular lipid used in the biopolymeric material plays a critical role in increasing or decreasing the sensitivity of the colorimetric transition. For example, a positional variation of the chromophoric polymer backbone can alter sensitivity to a given analyte.
- bacterial toxins such as cholera toxin from Vibrio cholerae and pertussis toxin, as well as antibodies. It is contemplated that further optimization will generate sensitive materials for the detection of many reactions, rearrangements, and analytes.
- the carbon chain length that positions the head group a specific distance from the polymer backbone in the final polymerized material is dependent on the position of the polymerizable group in an unassembled monomer.
- diacetylene liposomes some embodiments of the present invention demonstrated that a diacetylene group positioned from between the 18-20 positions to the 3-5 position in the monomers produced progressively more sensitive liposomes when used for the detection of analytes. Liposomes produced from monomers with the diacetylene groups from the 10-12 position to the 4-6 position provided particularly efficient control of sensitivity. Diacetylene groups positioned in about the 5-7 position are preferred for certain embodiments, such as cholera toxin detection.
- the production protocol for the monomer determines at which position the diacetylene group is placed in the final monomer product.
- the total carbon chain length in the unassembled monomer also influenced the level of sensitivity of the liposome product, although to a lesser extent than the position of the polymerizable group in the monomer carbon chain.
- the shorter chain length typically provided for greater sensitivity for. as determined in analyte-detecting embodiments.
- the monomers that are ideally useful in construction of the inventive colorimetric liposomes range from between C l2 to C 25 in length, although both longer and shorter chain lengths are contemplated by the present invention.
- a preferred range of monomer carbon chain length in the present invention is C 20 to C 23 .
- the biopolymeric materials of the present invention may further comprise one or more dopant materials.
- Dopants are included to alter and optimize desire properties of the biopolymeric materials. Such properties include, but are not limited to. colorimetric response, color, sensitivity, durability, robustness, amenability to immobilization, temperature sensitivity, and pH sensitivity.
- Dopant materials include, but are not limited to, lipids. cholesterols, steroids, ergosterols. polyethylene glycols, proteins, peptides. or any- other molecule ( e.g. , surfactants, polysorbate. octoxynol, sodium dodecyl sulfate, zwitterionic detergents, decylglucoside.
- deoxycholate diacetylene derivatives
- phosphatidylserine phosphatidylinositol.
- phosphatidylethanolamine phosphatidylcholine
- phosphatidylglycerol phosphatidic acid
- phosphatidylmethanol phosphatidylmethanol
- cardiolipin ceramide.
- Example 4 demonstrate that the addition of sialic acid-derived diacetylene monomers to liposomes comprising ganglioside and PDA provided a dramatic increase in colorimetric sensitivity and quantifiability to the detection of low levels of analyte. This improvement in colorimetric response using dopant is extremely beneficial when un-doped materials produce only weak signals.
- target lipids e.g. , lipids that contain the ligand or that are the substrate of an enzymatic reaction
- polymer backbone e.g. , ganglioside ligands
- dopants are added to alter the color of the biopolymeric material.
- the present invention provides liposomes that change from blue to red. but also blue to orange, purple to red, purple to orange, green to red, and green to orange.
- glutamine-derivatized PDA produced very dark blue (i.e. , almost black) liposomes.
- green liposomes were produced with cycles of annealing (i.e.. heating to approximately 80°C) and cooling (i.e. , to ambient temperatures) prior to polymerization.
- annealing i.e.. heating to approximately 80°C
- cooling i.e. , to ambient temperatures
- the present invention provides a dopant cocktail that is a mix of glucose and sialic acid-derived polydiacetylene.
- the glucose component of the dopant mixture appears to act primarily to prevent non-specific adhesion to the surface of the inventive liposome and may also enhance sensitivity.
- the polydiacetylene bound sialic acid component appears to functionally destabilize the surface to provide a dramatic increase in sensitivity for analyte detection.
- dopant lowers the activation barrier of the chromatic transition and/or provides a connection between the ligands (i. e. , if ligands are present) and the conjugated backbone, enabling the reactions to induce the colorimetric transition.
- dopants with bulky headgroups e.g. , sialic acid-derived lipid monomers
- dopants with bulky headgroups are subject to various solvent interactions at the matrix surface, destabilizing the structure of the blue film and thus allowing relatively small perturbations provided by the localized membrane rearrangements to complete the colorimetric transition.
- the dopant comprises a diacetylene or a modified diacetylene (e.g.. sialic acid derived diacetylene).
- the derivatized lipid is used to modify the properties of the biopolymeric material and is not used as a molecular recognition site for an analyte detection (e.g.. as in the case of sialic acid ligand used to detect influenza virus).
- analyte detection e.g.. as in the case of sialic acid ligand used to detect influenza virus.
- a diacetylene-based polymeric material containing only sialic acid derivatized monomer or lactose derivatized monomer did not respond to neurotoxins (e.g., botulinum neurotoxin), indicating that there was an insufficient interaction between the neurotoxins and the derivatized diacetylene lipid to induce the color change.
- ganglioside G M1 a ligand having affinity for neurotoxin
- a colorimetric response was detected in the presence of neurotoxin.
- the sialic acid and lactose derived lipids are "dopants" and the ganglioside G M1 is a ligand.
- dopant materials will find use in optimizing the properties of the biopolymeric material used in various embodiments of the present invention.
- Materials that are constituents of cell membrane structures in nature are generally useful as dopants in the present invention.
- steroids e.g. , cholesterols
- Surfactant type compounds also may serve as dopants, whether or not they are polymerized to self-assembling monomers that make up the polymer back bone.
- the detergent TWEEN 20 which does not contain a polymerizable group, has been shown to provide a very dramatic intensity to the blue color of the liposomes of certain embodiments of the present invention.
- peptide-detergents i.e.. small amphipathic molecules that have a hydrophobic region mimicking the membrane spanning regions of membrane proteins. These small peptides (typically 20-25 amino acids in length) can be incorporated into the biopolymeric material to alter the stability or sensitivity of the colorimetric response of the material. Since peptide-detergents are bulkier in the hy drophobic region of the material, they are capable of producing a more pronounced effect on film stability or sensitivity than many other surfactant molecules. The most appropriate percentage of dopant incorporated into the structure of the biopolymeric material is dependent on the particular system being developed, and the needs of the testing situation.
- sensitivity may be compromised to some extent in the fa ⁇ or of long shelf life, or to accommodate rigorous field conditions.
- the acceptable percentage of dopant is theoretically limited only to that which will not preclude sufficient incorporation of the indicator polydiacetylene molecules to produce the necessary optical density and color change or to that which will disrupt the stability of the polymeric structures.
- Molar percentages of dopant can vary from as low as 0.01% where increases of sensitivity have been observed in certain embodiments, to as high as 75%, after which the structural integrity of the biopolymeric material typically begins to deteriorate. However, there may be specific embodiments where the percentage of dopant is greater than 15% or lower than 0.01%. A preferred range for dopant is 2%-10%. In certain embodiments of the present invention, the optimal percentage of dopant is about 5% (See e.g. , Example 4, section II).
- cholera toxin For example, for the detection of cholera toxin, it was found that a film comprising 2% lactose-derivatized polydiacetylene (PDA), 5% ganglioside, and 93%) PDA resulted in a strong blue to red color change when the film was incubated with the analyte.
- PDA lactose-derivatized polydiacetylene
- the incorporation is very controlled, and requires several hours of processing. This relatively slow, gentle incorporation method allows the incorporation of comparatively large or complex dopant materials.
- the sonication bath approach is only suitable when it is intended that a relatively low percentage of dopant is to be incorporated.
- the point probe method allows the incorporation of a much higher percentage of dopant material over a shorter period of time, typically from one to ten minutes. However, this method is typically limited to incorporation of small to intermediate sized dopant materials.
- the temperature chosen for incorporation are selected based on the particular analytical system and liposome parameters desired. A practitioner will be able to select parameters such as pH, choice of dilutents. and other factors based on the particular system and desired characteristics of the biopolymeric material.
- a series of derivatized polydiacetylene dopant molecules have been synthesized with a wide range of physical characteristics. These dopants are not the same as filler molecules typically observed in biological membranes (i.e.. cholesterol, proteins, lipids. detergents). They differ in that they provide unique and specific functionality to a given sensor system. The design of several dopants that provide specific functionality to the non-synthetic embodiments are described below and in Example 4. A simple system has been designed so that the PDA molecule can easily be derh atized. The synthesis is shown in Figure 9. Here, 10, 12-pentacosadiynoic acid is modified to amine-couple to any molecule with a free amino group.
- the biopolymeric materials of the present invention may further comprise one or more ligands.
- Ligands act as a recognition site in the biopolymeric materials for analytes or as anchors for recruiting molecules or localizing reactions to the biopolymeric surface.
- a disruption of the polymer backbone of the biopolymeric material occurs, resulting in a detectable color transition.
- ligands are linked by a linking arm to the self-assembling monomers, directly linked to the monomers, incorporated into the biopolymeric matrix prior to or during the polymerization process, or attached to the matrix following polymerization (e.g.. by linking ligands to matrix constituents that contain head groups that bind to the ligands or through other means).
- Figure 1 1 provides a schematic depiction of one embodiment of the present invention.
- Compound 1 shows a receptor- binding ligand (i.e.. sialic acid) attached to one terminal end of a spacer molecule.
- the second terminal end of the spacer molecule is attached to one of several monomers (e.g... 10,12-pentacosadiynoic acid) that have been polymerized so as to form a chromatic detection element.
- Compound 2 shows the 10,12-pentacosadiynoic acid without an attached ligand.
- the ligand group of the present invention comprise a wide variety of materials.
- the main criterion is that the ligand have an affinity for the analyte of choice.
- Appropriate ligands include, but are not limited to, peptides, carbohydrates, nucleic acids. biotin. drugs, chromophores. antigens, chelating compounds, short peptides, pepstatin, Diels-Alder reagents, molecular recognition complexes, ionic groups, polymerizable groups, dinitrophenols. linker groups, electron donor or acceptor groups, hydrophobic groups, hydrophilic groups, antibodies, or any organic molecules that bind to receptors.
- the biopolymeric material can be composed of combinations of ligand-linked and unlinked monomers to optimize the desired colorimetric response (e.g. , 5% ligand-linked dicosadynoic acid [DCDA] and 95% DCDA). Additionally, multiple ligands can be incorporated into a single biopolymeric matrix. As is clear from the broad range of ligands that can be used with the present invention, an extremely diverse group of analytes can be detected. In some embodiments, the self- assembling monomers are not associated with ligands. but are directly assembled, polymerized, and used as colorimetric sensors. Such biopolymeric materials find use in the detection of certain classes of analytes including, but not limited to. volatile organic compounds (VOCs).
- VOCs volatile organic compounds
- ligands are incorporated to detect a variety of pathogenic organisms including, but not limited to, sialic acid to detect HIV (Wies et al . Nature 333: 426 [1988]). influenza (White et al . Cell 56: 725 [1989]), Chlamydia (Infect. Imm. 57: 2378 [1989]). Neisseria meningitidis, Streptococcus suis, Salmonella, mumps, newcastle. and various viruses, including reovirus, Sendai virus, and myxo virus; and 9-OAC sialic acid to detect coronavirus.
- sialic acid to detect HIV
- influenza White et al . Cell 56: 725 [1989]
- Chlamydia Infect. Imm. 57: 2378 [1989]
- encephalomyelitis virus and rotavirus; non-sialic acid glycoproteins to detect cytomegalovirus (Virology 176: 337 [1990]) and measles virus (Virology 172: 386 [1989]); CD4 (Khatzman et al. Nature 312: 763 [1985]). vasoactive intestinal peptide ( Sacerdote et al. J. of Neuroscience Research 18: 102 [1987]), and peptide T (Ruff et al.
- N-CAM N-CAM
- myelin-associated glycoprotein MAb Shephey et al , Proc. Natl. Acad. Sci. 85: 7743 [1988]
- polio virus receptor to detect polio virus
- fibroblast growth factor receptor to detect herpes virus (Kaner et al , Science 248: 1410 [1990]): oligomannose to detect Escherichia coli; ganglioside G MI to detect Neisseria meningitidis; and antibodies to detect a broad variety of pathogens (e.g., Neisseria gonorrhoeae, V. vulni ⁇ cus, V. parahaemolyticus. V. cholerae, and V. alginolyticus) .
- pathogens e.g., Neisseria gonorrhoeae, V. vulni ⁇ cus, V. parahaemolyticus. V. cholerae, and V. alginolyticus
- lipids with a diverse range of compounds (e.g. , carbohydrates, proteins, nucleic acids, and other chemical groups) are well known in the art.
- carboxylic acid on the terminal end of lipids can be easily modified to form esters, phosphate esters, amino groups, ammoniums. hydrazines, polyethylene oxides, amides, and many other compounds.
- These chemical groups provide linking groups for carbohydrates, proteins, nucleic acids, and other chemical groups (e.g., carboxylic acids can be directly linked to proteins by making the activated ester, followed by reaction to free amine groups on a protein to form an amide linkage).
- carboxylic acids can be directly linked to proteins by making the activated ester, followed by reaction to free amine groups on a protein to form an amide linkage.
- Examples of antibodies attached to Langmuir films are known in the art (See e.g.. Tronin et al . Langmuir 11 : 385 [1995]; and Vikholm et al . Langmuir 12: 3276 [1996]).
- the methods of the present invention provide a system to easily attach protein molecules, including antibodies, to the surface of polydiacetylene thin films and liposomes. thereby providing biopolymeric materials with "protein" ligands.
- ligands include, but are not limited to, peptides, proteins, lipoproteins, glycoproteins, enzymes, receptors, channels, and antibodies.
- analyte e.g. , enzyme substrate. receptor ligand. antigen, and other protein
- a disruption of the polymer backbone of the biopolymeric material may occur, resulting in a detectable color change.
- the present invention contemplates protein ligands that are incorporated into the biopolymeric material and those chemically associated with the surface of the biopolymeric material (e.g. , chemically linked to the surface head group of a monomer in the biopolymeric monomer).
- nucleic acids One characteristic property of nucleic acids is their ability to form sequence-specific hydrogen bonds with a nucleic acid having a complementary sequence of nucleotides. This ability of nucleic acids to form sequence-specific hydrogen bonds (i.e., to hybridize) with complementary strands of nucleic acids is exploited in the methods of the present invention. Nucleic acid having a known sequence (nucleic acid ligand) or desired hybridization characteristics is used as a "probe" to search a sample for a "target” complementary sequence. Target sequences are identified employing various nucleic acid ligands and the compositions and methods of the present invention.
- the target sequence, to which the probe region is complementary can be any whole or portion of genomic material, or nucleic acid gene product such as ribosomal, transfer, messenger or intron RNA, from any organism (including, but not limited to bacteria, viruses, parasites, and fungi) or cells (e.g., any eukaryotic or prokaryotic cells, including but not limited to cultured cells).
- Target sequences are typically in the order of several hundred nucleotides. although shorter and longer sequences are contemplated by the present invention.
- sequences characteristic of a human or non-human pathogen which includes any infectious microorganism
- human or non-human e.g., animal
- DNA or RNA sequences e.g., sequences characteristic of a genetic abnormality or other condition
- sequences derived from genetic engineering experiments such as, for example, total mRNA or random fragments of whole cell DNA.
- Methods for identifying target sequences and for preparing probe regions are well known in the art.
- the target sequence can also be, for example, complementary to a nucleic acid sequence characteristic of a class of human or non-human pathogens, for example, all enteric bacilli or all Chlamydia.
- the target sequence can also be, for example, complementary to a nucleic acid sequence characteristic of a host cell or vector used in the manufacture of recombinant DNA products (e.g., to detect the presence of such DNA or RNA contaminants in the product).
- nucleic acids which are complementary to (i.e., have affinity for) various target sequences identified above are contemplated as the nucleic acid ligands of the present invention.
- nucleic acid ligand contemplated by the present invention, include nucleic acid molecules which bind to. or interact with, other biological molecules (e.g., enzymes such as polymerases, nucleases, ligases. telomerases. and transcription factors). This type of binding depends upon the nucleotide sequence(s) that comprise the DNA or RNA involved. For example, short DNA sequences are known to bind to target proteins that repress or activate transcription in both prokaryotes and eukaryotes. Other short DNA sequences are known to serve as centromeres and telomeres of chromosomes, presumably by creating ligands for the binding of specific proteins that participate in chromosome mechanics. In this regard, nucleic acid molecules with sequences that are natural targets of biological molecules are contemplated as the nucleic acid ligands of the present invention.
- other biological molecules e.g., enzymes such as polymerases, nucleases, ligases. telomerases. and
- the present invention also contemplates nucleic acid ligands that are not the natural targets for biological molecules, but which are instead capable of binding to any desired analyte selected by the user.
- One technique used to identify such nucleic acids is called the SELEX procedure.
- the basic SELEX procedure is described in U.S. Pat. Nos. 5.475.096; 5,270.163; and 5,475.096; and in PCT publications WO 97/38134, WO 98/33941. and WO 99/07724, all of which are herein incorporated by reference.
- the SELEX procedure allows identification of nucleic acid molecules with unique sequences. each of which has the property of binding specifically to a desired target analyte or molecule.
- the SELEX procedure involves selection from a mixture of candidates of interest in step-w ise iterations.
- the SELEX procedure starts with a mixture of nucleic acids, preferably comprising a segment of randomized sequence.
- the mixture is contacted with a target (e.g . an analyte) under conditions favorable for binding.
- a target e.g . an analyte
- unbound nucleic acids are partitioned from those nucleic acids which have bound to target molecules.
- the nucleic acid-target pairs are dissociated and the nucleic acid is either amplified or isolated to yield a preparation enriched for target binding.
- the steps of binding, partitioning, dissociating and amplifying may be reiterated through as many cycles as desired.
- Nucleic acids that have the highest affinity constants for the target are most likely to bind. After partitioning, dissociation and amplification, a second nucleic acid mixture is generated that is enriched for the higher binding affinity candidates. Additional rounds of selection progressively favor the best ligands until the resulting nucleic acid mixture is predominantly composed of only one or a few sequences. These can then be cloned, sequenced and individually tested for binding affinity as pure ligands.
- the method may be used to sample as many as about 10' 8 different nucleic acid species in a test mixture.
- the nucleic acids of the test mixture preferably include a randomized sequence portion, as this portion provides a large number of possible sequences and structures with a wide range of binding affinities for a given target.
- a nucleic acid mixture comprising, for example a 20 nucleotide randomized segment can have 4 20 candidate possibilities.
- the present invention is not limited to a randomized segment of any particular length.
- the randomized portion may be from about 40 to 120 base pairs in length, while in other embodiments, the randomized portion may be from about 50 to 100 base pairs in length, and in some preferred embodiments, the randomized portion is from about 70 to 90 base pairs in length.
- the randomized portion is flanked by 5' and 3' fixed sequence regions.
- the fixed sequence regions are conserved sequences useful for efficient amplification (e.g., by PCR). Accordingly, the same pair of PCR primers can be utilized to amplify the randomized regions selected by the protocol.
- the fixed sequence regions are designed so that dimer formation and annealing between primers is minimized.
- the fixed regions include a promoter region (e.g., T3, T7. or SP6 promoter).
- the 5' fixed sequence region and 3' fixed sequence region are flanked by restriction sites to allow easy cloning of the entire nucleic acid including the fixed regions, or subcloning of the randomized region.
- Useful restriction sites include, but are not limited to. sites known in the art such as EcoRI. Hin ⁇ ll ⁇ . Psll. etc.
- Nucleic acid sequence variants can be produced in a number of ways including synthesis of randomized nucleic acid sequences and size selection from randomly cleaved cellular nucleic acids.
- the variable sequence portion may contain fully or partially random sequence: it may also contain subportions of conserved sequence incorporated with randomized sequence.
- Sequence variation in test nucleic acids can be introduced or increased by mutagenesis before or during the selection amplification iterations.
- Partitioning methods used in SELEX rely on a partitioning matrix. High affinity oligonucleotides may be separated using various methods, including chromatographic-type processes, binding to nitrocellulose filters, liquid-liquid partition, gel filtration, and density gradient centrifugation.
- the present invention contemplates screening a randomized pool of nucleic acid molecules for the ability to bind to various analytes, in order to use these nucleic acid molecules as nucleic acid ligands in the present invention.
- a composition comprising nucleic acids is provided.
- the mixture comprises greater than about 10 12 different nucleic acid sequences, while in particularly preferred embodiments, the mixture comprises greater than about 10 18 different nucleic acid sequences.
- the nucleic acids include a randomized portion.
- the randomized portion is from about 30 to 150 nucleotides in length. In still other embodiments, the randomized portion is from about 40 to 120 nucleotides in length.
- the randomized portion is from about 50 to 100 nucleotides in length. In some particularly preferred embodiments, the randomized portion is from about 70 to 95 nucleotides in length, while in other particularly preferred embodiments, the randomized portion is from about 50 to 60 nucleotides in length. Therefore, the present invention comtemplates nucleic acid ligands capable of binding to many types of analytes. Further examples of these these these analytes include, but are not limited to. pathogens, drugs, receptor ligands, antigens, ions, proteins, hormones, blood components, antibodies, and lectins.
- nucleic acid ligands identified above may also be included as a domain or portion of a larger nucleic acid molecule. Also, all of the nucleic acid ligands identified above can be conjugated to monomers as described below. (ii) Attachment of DNA to monomers
- self-assembling monomers were covalently attached to the 5 '-terminus of a single stranded DNA fragment, also referred to as oligodeoxynucleotide (ODN).
- ODN oligodeoxynucleotide
- the ODN-lipid conjugate was incorporated into diacetylene liposome assemblies.
- a common procedure for conjugation reactions with synthetic DNA is the modification of an oligodeoxynucleotide (ODN) in a DNA synthesizer with an amino function at the 5 '-end and cleaving and deprotecting the ODN to give a react e amine functionality capable of further reactions (See e.g.. Chatterjee et al , J. Am. Chem. Soc.
- DNA incorporation into liposomes using bacteriophage ⁇ to inject DNA into liposomes carrying the Shigella receptor has also been reported (New et al . Liposomes. A Practical Approach, first Ed.. Oxford University Press:New York [1990]).
- the 5' -OH terminus of a solid support bound 10-mer was conjugated with a diacetylene monophosphate using DCC.
- the ODN-lipid conjugates were mixed with liposomes which were then photopolymerized and filtered to remove unbound ODN.
- the amount of ODN retained with the liposomes was quantified by UV absorbance measurements at 260 nm.
- Interaction and inclusion of DNA in liposomes have been investigated, particularly as DNA delivery systems in gene therapy (See e.g.. New el al. supra).
- Cationic liposomes form layered complexes with parallel aligned DNA helixes sandwiched between lipid bilayers, exhibiting a liquid crystalline behavior (See e.g.. Radler et al . J. Am. Chem. Soc.
- the adsorption characteristics of ODN onto cationically charged latex particles were investigated in dependence of pH.
- Coulomb interaction between the positively charged surface and the negatively charged ODN, and hydrophobic interactions or H-bonding play an important role (See e.g., Ganachaud et al , Langmuir 13:701 -707 [1997]: and Ela ⁇ ssari et al, Langmuir 11 :1261-1267 [1995]).
- This hydrophobic interaction / H-bonding causes ODN to adsorb even on negatively charged surfaces, as was observed in PDA liposomes with exposed carboxylic acid headgroups at the liposome surface.
- single stranded probe DNA (ss-p-DNA) lipids are incorporated into preformed biopolymeric material with subsequent photopolymerization. This method requires synthesis of ss-p-DNA lipids. conjugation of the probe DNA with a diacetylene lipid, and subsequent insertion in the layer, followed by polymerization of the diacetylenes.
- the direct conjugation of the diacetylene lipid to the 5 " -end of the probe DNA could, for example, be achieved by treatment of the 5 " -OH- terminated oligonucleotide with POCl 3 /PO(OCH 3 ) 3 and the lipid alcohol, or by phosphorylation of the 5 " -OH-end with cyanoethyl phosphate/trichloroacetonitrile. followed by reaction with the lipid alcohol/trichloroacetonitrile.
- This method gives a rather low yield.
- ss-p-DNA could be linked to specific anchor lipids after photopolymerizaiton of the lipids. in order to circumvent photodegradation of the DNA.
- liposomes are immobilized covalently to a substrate surface for integration into colorimetric detection devices. This attachment can be achieved by incorporation of an anchor lipid which reacts specifically with functional groups exposed on the substrate surface.
- DNA fixation at polydiacetylene surfaces can be achieved by unspecific immobilization at amino or Al(III) phosphonate functionalized surfaces, or photocoupling of DNA to silica gel-bound psoralen.
- the DNA ligands provided a 30% colorimetric response to a hybridization event by complementary nucleic acid.
- the response was sequence-specific, as noncomplementary control oligonucleotides provided only 15%) response.
- the colorimetric change resulting from disruption of the biopolymeric material can be detected using many methods.
- a color shift was observed simply by visual observation.
- the present invention may be easily used by an untrained observer such as an at-home user.
- spectral test equipment well known in the art is employed to detect changes in spectral qualities beyond the limits of simple visual observation, including optical density to a particular illuminating light wavelength. For example, using a spectrometer, the spectrum of the material was measured before and after analyte introduction, and the colorimetric response (%>CR) was measured.
- the spectrum was then taken following analyte exposure and a similar calculation was made to determine the B tlnal .
- the present invention can be. if desired, attached to a transducer device.
- a transducer device See e.g. , Beswick and Pitt, J. Colloid Interface Sci. 124: 146 [1988]; and Zhao and Reichert, Langmuir 8: 2785 [1992]), quartz oscillators (See e.g.. Furuki and Pu. Thin Solid Films 210: 471 [1992]; and Kepley et al, Anal. Chem. 64: 3191 [1992]), and electrode surfaces (See e.g., Miyasaka et al , Chem. Lett., p.
- the present invention provides a double-check (i.e. , confirmation method) by observation of color change in the material.
- the biopolymeric materials of the present invention can be coated on thin PzT materials that oscillate at a resonance frequency, producing a microelectromechanical system (MEMS system).
- MEMS system microelectromechanical system
- Sensitivity can also be enhanced by coupling the lipid-polymer to a photoelectric device, colorimeter, or fiber optic tip that can read at two or more specific wavelengths. Also, the device can be linked to an alternative signalling device such as a sounding alarm or vibration to provide simple interpretation of the signal.
- analytes e.g., lipid cleavage activity of lipases and membrane modification activity of transferases
- the biopolymeric materials of the present invention can be used to detect a large variety of analytes including, but not limited to, small molecules, microorganisms, membrane receptors, membrane fragments. volatile organic compounds (VOCs), enzymes, drugs, antibodies, and other relevant materials by the observation of color changes that occur upon analyte binding.
- VOCs volatile organic compounds
- the present invention works under very mild testing conditions, providing the ability to detect small biomolecules in a near natural state and avoiding the risks associated with modification or degradation of the analyte.
- the present invention provides methods for detecting conformational alterations in the biopolymeric material by observation of colorimetric changes.
- conformational changes can be caused by the binding of an analyte to a ligand (described above) and through the chemical modification of the biopolymeric material by chemical reactions (e.g., enzymatic catalysis).
- the present invention provides a simple protocol using biopolymeric material and offers a practical approach to detecting interfacial catalysis, identifying inhibitors, and screening enzymes and other catalytic entities (e.g., catalytic antibodies) to characterize their catalytic capabilities.
- These methods use natural, unlabeled substrates, and catalysis or inhibition is signaled by the presence or lack of a color transition of the surrounding lipid-polymer assembly.
- the one-step nature of the technique allows for convenient adaptation to high throughput compound screening. This method is generally applicable to factors that affect enzyme recognition and activity, and influence membrane reorganization.
- Polymerized mixed vesicles are highly stable against chemical and physical degradation and offer a convenient, economical alternative to enzymatic assays that employ radiolabled substrates.
- the vesicle stock solutions described by the present invention have been stored for over six months without affecting the results of the assay.
- Specific applications of the present invention are described below to illustrate the broad applicability of the invention to a range of conformational changes and to demonstrate its specificity, and ease of use.
- Phospholipase A 2 phospholipase C, phospholipase D. bungarotoxin, and other enzyme activities are illustrated. These examples are intended to merely illustrate the broad applicability of the present invention; it is not intended that the present invention be limited to these particular embodiments.
- PLA 2 activity has previously been studied in a variety of model membrane systems such as polymerized vesicles (Dua et al , J. Biol. Chem. 270. 263 [1995]), micelles (Reynolds et al supra), and monolayers (Grainger et al, supra; and Mirsky et al , Thin Solid Films 284. 939 [1996]) using labeling techniques (e.g., radioactivity and fluorescence).
- labeling techniques e.g., radioactivity and fluorescence.
- the present invention provides biopolymeric materials incorporating PLA 2 substrate lipids for the colorimetric detection of PLA 2 enzyme activity.
- Biopolymeric materials were prepared with a combination of polymerizable matrix lipid (e.g.. 10.12-tricosadiynoic acid) and various mole fractions (0-40%) of PLA 2 substrate lipid (e.g.. dimyristoylphosphatidylcholine [DMPC]) as described in Examples 1 and 10.
- PLA 2 substrate lipid e.g.. dimyristoylphosphatidylcholine [DMPC]
- the biopolymeric materials containing the PLA 2 substrate lipid were liposomes as shown in Figure 12.
- This figure shows DMPC substrate in a diacetylenic lipid matrix before (top) and after (bottom) polymerization. In their initial state, the vesicles appeared deep blue to the naked eye and absorbed maximally at around 620 nm. as shown in Figure 13 (solid line).
- the suspension Upon addition of PLA 2 to the DMPC/PDA vesicles, the suspension rapidly turned red (i.e. , within minutes) and
- the color change was modulated by altering the mole percentage of the natural lipid DMPC in the PDA vesicle as shown in Figure 14. A relative color change of 10%) or more is clearly observed with the naked eye. Within minutes, liposomes containing greater than 20% DMPC exhibited strong colorimetric responses. Liposomes with low molar ratios of DMPC (e.g.. 5%) also showed visually detectable colorimetric response after longer incubations. Vesicles that did not contain DMPC, remained largely in their blue phase upon addition of PLA 2 as shown in the control sample. Biochromic transitions of PDA vesicles and films have been proposed to arise from perturbation of the extended ⁇ -overlap of the conjugated polymer backbone.
- PLA 2 activity was independently measured using a labeled lipid analog incorporated into the PDA matrix, allowing simultaneous measurement of product formation and colorimetric response of the vesicles.
- the analog used was thioester 1 ,2-bis-(S-decanoyl)- 1.2-dithio-sn-glycero-3-phosphocholine (DTPC).
- Figure 16 features 3 I P NMR spectra of the DMPC/PDA vesicles prior to the addition of PLA 2 (Figure 16A), and following the enzymatic reaction ( Figure 16B).
- the relatively broad, anisotropic J 1 P resonance from the intact vesicles, Figure 16A corresponds to the choline head-group of DMPC embedded in the PDA vesicles.
- the observation of j l P anisotropy in Figure 16A indicates that DMPC molecules are immobilized within the vesicle matrix.
- the assay test for phospholipase D and C were run under similar conditions as the PLAT assays. Both PLD and PLC activity were successfully detected by the liposomes assay. The PLD assay yielded a final colorimetric response of approximately 55%.
- the shape of the response curve was more gradual than that of PLA ⁇ .
- the kinetics of the PLD-catalyzed reaction are different or that the response time between the catalytic event and the color change is slower.
- the PLC assay yielded a final colorimetric response of 60% and the response curve was similar to that of PLA 2 .
- NMR experiments further verified the occurrence of interfacial catalysis by PLC and PLD.
- Bungarotoxin (BUTX) ⁇ -bungarotoxin, a snake toxin from Bungarus multicinctus, is known to destroy svnaptic vesicles and inhibit acetylcholine release. It is classified as a PLA 2 toxin and is composed of two subunits: a 12-kDa subunit that exhibits PLA 2 activity and a 7.5-kDa subunit that shares sequence homology with protease inhibitors.
- This bungarotoxin assay provides an example of a large molecular assembly possessing enzymatic properties that is capable of producing a colorimetric change in the biopolymeric materials.
- additional bungarotoxin-detecting features for example, antibodies raised against bungarotoxin (i.e. , ligands) can be incorporated onto the biopolymeric materials in addition to DMPC.
- the present invention will find use in detecting, measuring, and characterizing the enzyme activities of many other systems including, but not limited to, lipolytic enzymes.
- acyltransf erases, protein kinases, glycosidases, isomerases, ligases, polymerases, and proteinases. among others.
- Such enzymes can be free in solution, or be part of larger molecular aggregates, cells, and pathogens.
- Dordick Dordick. Biocatalysts for Industry, Plenum Press [1991]
- glycosidases can be detected to measure their activity or as indicators of the presence of a pathogen.
- Sialidases such as neuraminidase are found on influenza virus, and other sialidases are associated with Salmonella. By providing biopolymeric materials with substrate for the glycosidases, the presence of the pathogens can be detected. In combination with other detection elements (e.g. , sialic acid ligands for detection of influenza virus), extremely sensitive colorimetric sensors can be produced.
- detection elements e.g. , sialic acid ligands for detection of influenza virus
- Substrates can also be provided to produce detection systems for proteinases. For example. Candida albicans can be detected though its protease activity on pepstatin substrates. Also, anthrax spores from Bacillus anthracis can be detected by identifying laccase activity though its reaction with a substrate. Laccases are multi-copper-containing enzymes that catalyze oxidative conversion of a variety of substrates, including phenols, poly-phenols, and aromatic amines. Specific substrates include vanillic acid, syringic acid, and 2-2 " -azino-bis(3-ethyl-benzthioazoline-6-sulfonic acid).
- a detection assay for antrax spores may be generated.
- Other applications include incorporation of nucleic acids onto the biopolymeric material to test the activity of nucleotide polymerases (e.g., DNA polymerase).
- nucleotide polymerases e.g., DNA polymerase.
- the present invention provides methods for detecting the activity of enzymes and other molecules that alter the conformation of biopolymeric membranes. These methods can be expanded to provide an accurate, and fast screening technique for identifying and characterizing inhibitors of the activity responsible for the colorimetric change (e.g., identifying and characterizing protease inhibitors by subjecting candidate inhibitors to biopolymeric materials comprising the protein substrates for the enzymes).
- the color change of the DMPC/PDA vesicles can be suppressed by using inhibitors to PLA 2 .
- the vesicles remained in their blue phase upon addition of PLA 2 .
- the vesicles also do not change color in the presence of other enzymes such as lysozyme and glucose oxidase, both of which produce a colorimetric response below 5% after more than an hour of incubation with the 40%) DMPC/PDA vesicles.
- the specificity of the colorimetric response provides the necessary selectivity for high throughput screening of enzyme inhibitors.
- biopolymeric material comprising a substrate for the enzyme being tested, are placed into a multi-chambered device (e.g., a 96-well plate). Each well is incubated with a sample suspected of containing an enzyme inhibitor. The enzyme is then added and the observation of a color change is detected. Successful inhibitors will partially or completely prevent the enzyme from producing a color change in the biopolymeric material. Appropriate control samples (e.g. , a sample with no inhibitor and a sample with known inhibitor) are run with the assay to provide confidence in the results.
- the biopolymeric materials of the present invention further provide methods for screening the efficacy and activity of "designed" proteins, peptides. and catalytic antibodies.
- a simple, accurate screen of these engineered proteins can be conducted under a variety of test conditions.
- the inventive methods can be used to screen and characterize the reactions of catalytic antibodies.
- the biopolymeric material of the present invention can be immobilized on a variety of solid supports, including, but not limited to polystyrene, polyethylene, teflon, silica gel beads, hydrophobized silica, mica, filter paper (e.g., nylon, cellulose, and nitrocellulose). glass beads and slides, gold and all separation media such as silica gel. sephadex. and other chromatographic media.
- the biopolymeric materials were immobilized in silica glass using the sol-gel process.
- Immobilization of the colorimetric biopolymeric materials of the present invention may be desired to improve their stability, robustness, shelf-life, colorimetric response. color, ease of use. assembly into devices (e.g.. arrays), and other desired properties.
- placement of colorimetric materials onto a variety of substrates surfaces can be undertaken to create a test method similar to the well-known and easv to use litmus paper test.
- the reflective properties of nylon filter paper greatly enhance the colorimetric properties of the immobilized polydiacetylene liposomes. Filter paper also increases the stability of the liposomes due to the mesh size.
- the liposome embodiment of the present invention has been loaded into the ink cartridge of a inkjet printer and used to print biopolymeric liposome material onto paper as though it were ink.
- the liposome material present on the paper maintained its colorimetric properties.
- This embodiment demonstrates the ease with which patterned arrays can be generated into any desired shape and size. By using multiple cartridges (e.g.. using a color printer), patterned arrays can be generated with different biopolymeric materials.
- liposome layers on thin support i.e. , printing paper, plastic sheets, overhead transparencies, etc.
- the printer was used by filling the printing cartridge with the liposome solution. This allowed patterning in the range from several tens of cm down to the sub mm region (resolution limit of the printer), and the pattern was easily designed and printed from any personal computer application (e.g. , drawing program, word processor).
- the printed liposomes were photopolymerized after drying with the resulting polymer being strongly absorbed, and even organic solvents like acetone or CH 2 C1 2 did not dissolve the created pattern.
- This method represents an ideal approach to the generation of test stick type applications or array type assays.
- An additional advantage is the efficient use of the liposome material which is applied in thin films, and used completely in the assay (i. e.. no loss due to washing or functionalization steps).
- the general working procedure consists of the following steps: i) preparation of the liposome solution (>5 ml, 2-10 mM) and filling of the cartridge with it; ii) priming and flushing of the cartridge with an ink intensive print pattern immediately followed by- printing of the desired liposome pattern; and iii) photopolymerization of the liposome printout.
- Embodiments of the present invention provide for the successful immobilization of spherical, bilayer lipid aggregates, and liposomes using an aqueous sol-gel procedure.
- These molecular structures, and particularly liposomes. composed of biological or biomimetic (i.e.. mimics nature) lipids. are fairly robust under aqueous conditions and ambient temperatures, but can easily degrade in the presence of organic solvents and high temperatures.
- the sol-gel process provides a facile method of immobilizing molecular aggregates with no detectable structure modification, creating robust structures that are easily fabricated into any desired size or shape.
- the silica sol-gel material was prepared by sonicating tetramethylorthosilicate.
- metal oxides other than tetramethylorthosilicate. are contemplated by the present invention, so long as they facilitate the entrapment and form substantially transparent glass material.
- metal oxides include, but are not limited to, silicates, titanates, aluminates, ormosils, and others.
- Buffer was then added to the acidic solution under cooling conditions.
- the biopolymeric materials, generated as described above, were mixed into the buffered sol solution. This composite was poured into a desired molding structure and allowed to gel at ambient temperatures.
- the present invention be limited by the type of molding structure used, as it is contemplated that a variety of structures can be applied to generate gels of any desired size and shape including, but not limited to. cuvettes, flat surfaces for generating thin films, plastic, ceramic, or metal moldings to generate badges, etc. It is not intended that the present invention be limited to gelation at ambient temperatures, as any temperature range that facilitates the production of functional analyte-detecting gels is contemplated.
- DCDA liposomes were incorporated into sol-gel glass, although incorporation of any biopolymeric structure is contemplated by the present invention.
- gelation occurred within a few minutes, producing gels with a violet color.
- the visible absorption spectra of the polydiacetylene liposomes. as shown in Figure 18, was unaltered in the sol-gel matrix compared to liposomes in solution.
- a blue to red thermochromic transition occurred that was characteristic of polydiacetylene materials.
- the blue to red phase materials were similarly unchanged in the sol-gel state compared to solution as shown in the spectrum in Figure 19.
- the present invention provides a sol-gel matrix that is compatible with fragile biopolymeric structures (i.e., liposomes) and maintains those physical properties that were observed in bulk solution.
- sol gel prepared materials of various thicknesses will possess unique sensitivities to analytes. Thicker films have a higher surface to volume ratio and therefore may require a higher concentration of analyte to trigger the chromatic transition.
- the gelling conditions of the sol-gel preparation can be optimized by- varying gelling temperatures, gel materials, and drying conditions to generate material with desired pore sizes. Varying the crosslink density of the material also provides control over pore size. Pore sizes from nanometers to hundreds of nanometers or greater are contemplated by the present invention. Some gels allow size-selective screening of undesired material while maintaining analyte access to the ligand. Also, the sol-gel technique allows structures to be formed that can be molded into any desirable shape, including, but not limited to. cartridges, coatings, monoliths, powders, and fibers.
- the biopolymeric material can be attached to membranes of poly(ether urethanes) or polyacrylonitrile. These membranes are porous, hydrophilic and can be used for affinity separations or immunodiagnosis.
- the liposomes of the present invention can be coupled to these membranes by first attaching an activating group such as imidizolyl-carbonyl. succinimido, FMP or isocyanate to the membrane which adds rapidly to nucleophiles (e.g., -NH 2 , -SH. or -OH groups) present in the liposomes.
- nucleophiles e.g., -NH 2 , -SH. or -OH groups
- materials which have an -SH functionality can also be immobilized directly to gold surfaces, particles, or electrodes via the thiol-gold bond.
- a solution of the liposomes containing the -SH group are incubated with the clean gold surface in water for 12-24 hours with stirring at room temperature.
- materials can be immobilized to silicon chips or silica gel (e.g., silicon dioxide) using the procedure described in Example 8.
- materials containing - NFL functionalities can also be immobilized onto surfaces with standard glutaraldehyde coupling reactions that are often used with the immobilization of proteins.
- liposomes can be attached through their carboxy groups to surfaces comprising polyethyleneimine. a branched polymer with free amine groups.
- Certain embodiments of the present invention contemplate the generation of a large palette of polymerizable lipids with different headgroup chemistries, ligands, dopants, monomers or other properties within a single device to increase selectivity, sensitivity, quantitation. ease of use, and portability, among other desired characteristics and qualities.
- array format By using the array format, several advantages can be realized that overcome the shortcomings of a single sensor approach. These include the ability to use partially selective sensors and to measure multicomponent samples. This offers the possibility of sensing a specific sample in the presence of an interfering background, or to monitor two or more samples of interest at the same time. The sensitivities of a given lipid to a given sample can be determined in order to generate identifiable fingerprints characteristic of each sample.
- the response fingerprint orange/pink/purple/blue- purple would indicate the presence of sample X.
- the higher the number of elements in the array the greater the chance of a positive identification for a given analyte.
- Arrays can be generated that measure both the presence and activity of samples. For example, when characterizing a certain enzyme, one portion of the array can provide analyte-detecting capabilities for the enzyme (e.g., by incorporating a ligand that interacts with the enzyme), while another provides and enzyme activity assay (e.g. , by including a substrate for the enzyme within the biopolymeric material).
- Such arrays can be expanded for use in inhibitor screening techniques where each portion of the array provides quantitative or qualitative data, or provides a control experiment.
- the self-assembling monomers to be incorporated into the liposomes were dissolved in solvent (e.g.. chloroform for diacetylenes and methanol for ganglioside G M I ).
- solvent e.g.. chloroform for diacetylenes and methanol for ganglioside G M I .
- solvent solutions were mixed in appropriate volumes in a brown vial (i.e.. to prevent light interference during the upcoming drying steps) to achieve the desired lipid mixture (e.g.. 5% by mole of G M 1 , 95%) diacetylenes) and a total lipid content of approximately 2 ⁇ mol.
- the solvent was then evaporated by rotary evaporation or with a stream of nitrogen gas.
- the dried lipids were resuspended in sufficient de-ionized water to produce a 1-15 mM solution of lipid.
- the solution was then sonicated for 15-60 minutes with a probe sonicator (Fisher sonic dismembrator model 300, 50%) output, microtip) as described by New (New, supra).
- the solution was heated during the sonication (in most cases the sonicating process alone provides sufficient heat) to a temperature above the phase transition of the lipids used (typically 30-90 °C).
- the resulting mixture was filtered through a 0.8 micromole nylon filter (Gelman) or through a 5 mm Millipore Millex-SV filter and cooled to 4°C for storage or was polymerized.
- oxygen in the solution was removed by bubbling nitrogen through the sample for 5-10 minutes.
- Polymerization of the stirred liposome solution was conducted in a 1 cm quartz cuvette with a small 254 nm UV-lamp (pen-ray. energy: 1600 microwatt/cm 2 ) at a distance of 3 cm.
- the chamber was purged with nitrogen during the polymerization to replace all oxygen and to cool the sample.
- Polymerization times varied between 5 and 30 minutes depending on the desired properties (e.g. , color, polymerization degree) of the liposomes.
- the solution was placed in a UV-chamber, without purging, and exposed to 0.3-20 J/cm 2 of ultraviolet radiation, preferably 1.6 J/cm 2 , for 5- 30 minutes.
- polymerization was conducted in a multi-chambered plate (e.g. , ELISA plate). Approximately 200 ⁇ l of sonicated liposome solution was placed in each well of the plate. The plate was placed under a UV lamp with the distance between the plate and the lamp kept at 3 cm. Irradiation times typically lasted for a minute. Prolonged irradiation resulted in formation of pink/purple liposomes, indicating that a color change was initiated by UV light. Such liposomes gave inconsistent results and should be avoided.
- a multi-chambered plate e.g. , ELISA plate.
- Polydiacetylene films were formed in a standard Langmuir-Blodgett trough (See e.g.. Roberts, Langmuir Blodgett Films, Plenum. New York [1990]).
- the trough was filled with water to create a surface for the film.
- Distilled water was purified with a millipore water purifier with the resistivity of 18.2 M-Ohm.
- Diacetylene monomers e.g.
- the film was physically compressed using moveable barriers to form a tightly-packed monolayer of the self-assembling monomers.
- the monolayer was compressed to its tightest packed form (i.e. , until a film surface pressure of 20-40 mN/m was achieved).
- the film was polymerized.
- Certain embodiments (e.g., embodiments with dopants) of the present invention may require surface pressure compression greater or less than 20-40 mN/m.
- Ultraviolet irradiation was used to polymerize the monomers, although other means of polymerization are available (e.g. , gamma irradiation, x-ray irradiation, and electron beam exposure). Pressure was maintained on the film with the moveable barriers throughout the irradiation process at surface pressure of 20-40 mN/m. An ultraviolet lamp was placed 20 cm or farther from the film and trough. It was found that if the lamp is placed closer to the film, damage to the diacetylene film may occur due to the effects of heating the film. The film was exposed to ultraviolet light with a wavelength of approximately 254 nm for approximately one minute. The polymerization was confirmed by observing the blue color acquired upon polymerized diacetylene formation and detecting the linear striations typical of polymerized diacetylene films with a polarizing optical microscope.
- Self-assembling monomers to be incorporated into the tubules were dissolved in solvent, mixed together, evaporated, and resuspended in water as described above for liposomes. 1 -10% by volume of ethanol was added to the solution, although other organic solvents are contemplated by the present invention. The solution was then sonicated (with heating if necessary), filtered, cooled, and polymerized as described above for liposomes.
- Diacetylene films were prepared in a Langmuir Blodgett trough as described above using a combination of PDA monomers and sialic acid-derived PDA monomers.
- the floating polymerized assembly was lifted by the horizontal touch method onto a glass slide previously coated with a self-assembled monolayer of octadecyltrichlorosilane (OTS) as described (Maoz and Sagiv. J. Colloid Interface Sci. 100: 465 [1984]).
- OTS octadecyltrichlorosilane
- the slide was then examined by optical microscopy with the use of crossed polarizers as described (Day and Lando, Macromolecules 13: 1478 [1980]).
- the films were further characterized by angle-resolved x-ray photoelectron spectroscopy (XPS) and ellipsometry.
- XPS x-ray photoelectron spectroscopy
- the XPS results indicated that the amide nitrogen atoms and the carbonyl carbon atoms of the head groups were localized at the surface relative to the methylene carbons of the lipid chains, demonstrating that the sialoside head group was presented at the surface of the film.
- Ellipsometric analysis of the polydiacetylene monolayer coated on HF-treated silicon indicated a film thickness of approximately 40 A, in agreement with the expected value based on molecular modeling.
- the present invention provides a variety of different biopolymeric material forms (e.g.. liposomes. films, tubules, etc.). with and without dopant materials, with a variety of ligands. and immobilized in a variety of forms.
- biopolymeric material forms e.g.. liposomes. films, tubules, etc.
- dopant materials e.g., boron, boronitride, boronitride, etc.
- ligands ligands.
- immobilized in a variety of forms e.g., ligands, etc.
- the biopolymeric material of the present invention can comprise a sample of pure monomers (e.g.. pure diacetylene) or can comprise mixed monomers (e.g., PDA with Ganglioside G M , or dopant). Optimization of the percent composition of mixed monomers can be undertaken to provide biopolymeric material with desired properties. An example of such optimization is provided below for the detection of an analyte (/ ' . e.. cholera toxin) with a ganglioside ligand.
- Figure 21 summarizes the colorimetric properties and response of the G M 1 biosensing monolayer films studied in these experiments showing the initial absorbance. transfer rate, and colorimetric response in buffer and in response to analyte.
- the initial absorbance (A mu ) which reflects the maximal peak value of the films at 640 nm, is a function of the film transfer rate and composition.
- G M which does not provide chromatic functionality into the mixed assembly, generally decreases the intensity of the initial blue color.
- the transfer rate which is the ratio of the area decreased on the tough surface and the area of the substrate emerged into the subphase, indicates that the PDA films are highly transferable as compared to those of sialic acid-PDA (SA-PDA) and G M 1 molecules.
- SA-PDA sialic acid-PDA
- G M 1 molecules The blue to red colorimetric response (CR) shows that monolayer films exhibit low CR in buffer solution except when high content of G M1 or SA-PDA is used.
- the ionic content of the aqueous subphase has significant impact on the properties of Langmuir monolayers.
- the presence of cationic species strengthens the electrostatic interaction of monolayer with anionic headgroups and consequently stabilized the film (Gaines, Insoluble Monolayers at Liquid-Gas Interface, Interscience Publishers, New York, pp 291-299 [1966]).
- Figure 22 shows the isotherms of 5% G M I /5% SA-PDA/90% PDA as a function of subphase concentration of CdCl 2 . As the concentration of Cd 2* is increased, the expanded phase shifts systematically toward the low molecular area, indicating that the monolayer is stabilized at high Cd 2* concentration.
- FIG 23 shows the isotherms of 5% G M1 /5% SA-PDA/90% PDA at pH 4.5, 5.8, and 9.2.
- pH 9.2 the film became very expanded as a result of electrostatic repulsion between the adjacent PDA molecules. Compression of such a film to form a monolayer was difficult. Additionally, distinct segments of individual molecules were observed, pointing to an immiscible trend in the mixed monolayer that tends to form segregated domains.
- high charge density at the monolayer interface created unfavorable interactions on the aqueous surface.
- Figure 24 displays the temperature effect on the isotherms of 100% PDA, 5%SA-PDA/95% PDA, and 5% G M ] /5%> SA-PDA '90%) PDA.
- the surface pressure increased and the isotherm shape changed.
- Isotherms at low temperature exhibited more and more liquid-solid phase transition features, as indicated by the disappearance of the peak and occurrence of the smooth curve at the transition region.
- All the ⁇ -A isotherms obtained for the three monolayers display similar characteristics. The major difference between these figures is the position of collapse point, which is a function of film composition.
- the colorimetric response was significantly reduced.
- the enhanced sensitivity observed with the 5.7-docosadiynoic acid liposomes arises from the positioning of the optical reporter group nearer to the interface (i.e., three methylene units compared to eight).
- SA-PDA function of SA-PDA is to provide the metastable state of the films for biomolecular recognition through a stress-induced mechanism (Charych et al , Chem. and Biol. 3: 1 13 [1996]).
- a film consisting of 1% G M] /1% SA-PDA/98% PDA was also investigated. The CR turned out to be low and it did not yield a useful colorimetric biosensor. As shown in Figure 21, the optimal colorimetric sensor was determined to be 5% G M j /5% SA- PDA/90%) PDA. Thus, a 5% molar content of the dopant SA-PDA provides the best sensor for detection of cholera toxin.
- Hydrophobic amino acids linked to diacetylenes can be used to lower the solubility of the biopolymeric material as well as the stability of the films or liposomes.
- These derivatized PDA ' s can be useful in the assembly of complex systems to fine tune the stability and sensitivity, two factors that are directly coupled to one another.
- the stability of films and liposomes can be greatly increased, under a variety of environmental conditions. Although a large gain in stability is seen, it is at a cost to sensitivity. A balance between sensitivity and stability has to be optimized.
- Acidic and basic amino acids linked to diacetylenes can be used to increase the solubility of the material. Specifically, these changes allowed polydiacetylene lipids to mix with water soluble biological molecules. Ordinarily, PDA is not water soluble and organic solvents are necessary (i.e., which can be destructive to biological molecules). By placing acidic or basic head groups onto the PDA molecule, the solubility of the derivatized PDA ' s were greatly enhanced. They also produced much brighter colors and were more consistent in the assembly of sensors. These results were likely due to the increase in water solubility and homogeneity of mixing between all components. The acid/base PDA ' s were by far the most sensitive of the amino acid-derived diacetylenes.
- colorimetric biosensors can be made with the addition of fluorescent properties. This provides a multi-purpose and more sensitive sensor.
- Ligands can be covalently linked to the head groups of self-assembling monomers (e.g.. sialic acid linked to diacetylene monomers), can be covalently linked to the surface of polymerized materials (e.g., proteins and antibodies with multiple amine and thiol linkages to the material surface), or can be non-covalently incorporated into the biopolymeric material (e.g., ganglioside incorporated into the membrane of films and liposomes).
- self-assembling monomers e.g.. sialic acid linked to diacetylene monomers
- polymerized materials e.g., proteins and antibodies with multiple amine and thiol linkages to the material surface
- non-covalently incorporated into the biopolymeric material e.g., ganglioside incorporated into the membrane of films and liposomes.
- the self-assembling monomers can be synthesized to contain a large variety of chemical head-group functionalities using synthesis techniques common in the art.
- the ligands are then joined to the self-assembling monomers through chemical reaction with these functionalities using synthesis methods well known in the art.
- the functionalities include, but are not limited to. esters, ethers, amino, amides, thiols, or combinations thereof.
- many ligands can be incorporated into the self- assembling matrix without covalent linkage to the surfactants (e.g. , membrane proteins and molecules with hy drophobic regions such as gangliosides and lipoproteins).
- Sialic acid was attached as a ligand to diacetylene monomers.
- Several synthesis methods well known in the art can be used, many of which have general applicability to the attachment of carbohydrates to the inventive biopolymeric materials.
- PDA 1.0 g, 2.7 mmol in chloroform
- NHS N-hydroxy succinimide
- EDC l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride
- the solution was stirred for 2 hours followed by evaporation of the chloroform.
- the residue was extracted with diethyl ether and water.
- Tetraethylene glycol diamine (1.26 g, 6.60 mmol) in 25 ml of chloroform was added to a solution of N-succinimidyl-PDA (.603 g, 1.28 mmol) in 20 ml of chloroform, dropwise. with stirring, over a period of 30 minutes.
- the reaction was stirred for an additional 30 minutes before removal of the solvent by rotary evaporation.
- the residue was dissolved in EtoAc and extracted twice with water.
- the organic layer was dried with MgS0 . and the solvent removed by rotary evaporation.
- Ethyl-5-N-acetyl-4.7.8.9-tetra-0-acetyl-3.5-dideoxy-2-C-(acetic acid)-D-erythro-L- manno-nonate (0.194 g, 0.35 mmol) was added to a cooled solution (5 °C) NHS (0.058 g. 0.50 mmol) and EDC (0.096 g, 0.50 mmol) in 2 ml of chloroform, under nitrogen. The reaction was warmed to ambient temperature with stirring for 5 hours. The reaction was then diluted with 15 ml of chloroform and washed with 1 N HCl (aq.).
- the solution was diluted with 15 ml of chloroform and washed with sodium chloride saturated IN FIC1 (aq.), twice; saturated (aq.) sodium bicarbonate, twice: and saturated (aq.) sodium chloride, once.
- the organic layer was dried over MgS0 4 , filtered, and evaporated to a crude semi-solid.
- the material was flash chromatographed over silica (20:1 CHCl 3 :MeOH), producing ethyl-5-N-acetyl-4,5,8,9-tetra- 0-acetyl-3.5-dideoxy-2-C-[(N-l r-(PDA)-3',6'.9 " -trioxyundecanyl) acedamido]-D-erythro- L-manno-nononate.
- the sialic acid derived-PDA was formed by dissolving ethyl-5-N-acetyl-4, 5.8,9- tetra-0-acetyl-3.5-dideoxy -2-C-[(N-l l ' -(PDA)-3',6',9'-trioxyundecanyl) acedamido]-D- erythro-L-manno-nononate (0.20 g. 0.19 mmol) in a solution of 4 ml of water and 0.5 ml of methanol containing 0.1 g dissolved sodium hydroxide.
- carbohydrates i.e.. including sialic acid
- the N-allyl glycosides can then be easily linked to other molecules (e.g. , PDA) using simple chemical synthesis methods known in the art.
- PDA simple chemical synthesis methods known in the art.
- This method provides a means to incorporate a broad range of carbohydrates into biopolymeric material (and thus provides a means to detect a broad range of analytes).
- oligosaccharides are dissolved in neat allyl amine (water may be added if necessary and does not adversely affect the yield) producing a 0.5-0.1 M solution. The reaction is stopped and stirred for at least 48 hours.
- the solvent is removed by evaporation and the crude solid is treated with toluene and evaporated to dryness several times. The solid is then chilled in an ice bath and a solution of 60%) pyridine. 40% acetic anhydride is added to give a solution containing five hundred mole percent excess of acetic anhydride. The reaction is protected from moisture, stirred and allowed to warm to ambient temperature overnight. The solvents are removed by evaporation and the residue is dissolved in toluene and dried by evaporation several times. The crude product is purified by flash chromatography producing the peracetylated NAc- allyl glycoside form of the free sugars.
- Ganglioside G M 1 presents an example of incorporation of a ligand without covalent attachment to the self-assembling monomers.
- Ganglioside G M was introduced in the biopolymeric material by combining a solution of methanol dissolved ganglioside G M I (Sigma) with chloroform dissolved PDA, and dried.
- the ganglioside contains a hydrophobic region that facilitates its incorporation into self-assembling surfactant structures.
- the dried solutions were resuspended in deionized water, the resulting structures contained a mixture of ganglioside and PDA. Liposomes and other forms were produced from the resuspended mixture as described in Example 1.
- the ganglioside does not contain a polymerizable group, the ganglioside became embedded in the polymerized matrix created by the cross-linking of the diacetylenes. Similar methods can be used for the incorporation of other ligands that contain hydrophobic regions (e.g.. transmembrane proteins and lipoproteins).
- the NHS-PDA as generated above, thiol-linked PDA, and other methods known in the art provide functional groups for the attachment of proteins and antibodies.
- the NHS or thiol-linked monomers are incorporated into the desired aggregate and polymerized.
- the NHS or thiol functional groups then provide a surface reaction site for covalent linkage to proteins and antibodies using chemical synthesis reactions standard in the art.
- a hydrazide functional group can be placed on PDA, allowing linkage to aldehydes and ketone groups of proteins and antibodies.
- NHS-PDA lipid was synthesized as described above.
- 1.00 g 10,12- pentacosadiynoic acid (Farchan, Gainesville, FL) was dissolved in CHC1 3 , to which 0.345 g N-hydroxysuccinimide (NHS) and 0.596 g l -(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride were added.
- the solution was stirred at room temperature for two hours, followed by removal of CHC1 3 using a rotavap.
- the residue was extracted with EtOAC and water. After separation, the organic layer was dried with MgS0 and filtered, followed by solvent removal.
- the raw product was then recrystallized twice with CHC1 3 . and confirmed by FT-IR.
- the 1 : 1 (molar ratio) PDA/NHS-PDA chloroform solution was spread on the aqueous subphase on a Langmuir-Blodgett trough (KSV mini-trough, KSV Instruments, Inc.. Finland) by using a microsyringe (subphase temperature was maintained at 5 °C).
- the organic soh ent was allowed to evaporate by resting the solution for 20 min.
- the films were compressed to compact monolayer level and then transferred by vertical deposition to glass slides coated with octadecyltrichlorosilane (OTS). The compression and dipping speed was maintained at 5 mm/min. Three layers were deposited onto the glass slide to provide enough colorimetric signal for detection after polymerization and to ensure the hydrophilic surface was exposed to solution.
- the preparation of stable PDA monolayer films before enzyme immobilization is critical for low background and enhanced reproducibililty of the sensors.
- the Langmuir monolayer trough provides a method to measure film stability through the evaluation of the surface collapse pressure of the monolayers. It was found that the mixed films (i.e. , films with PDA and NHS-PDA) appear to be much more stable than the monolayers consisting of one component and thus more suitable for enzyme immobilization. For instance, the collapse pressure for 1 : 1 NHS-PDA/PDA monolayer at 5 °C was 57 mN/m. while NHS-PDA and PDA monolayers collapsed at 34 and 28 mN/m, respectively.
- the interactions are more favorable in these mixed monolayers, presumably due to the optimal spatial arrangements that allow head groups of different size to pack closely.
- the monolayers should possess desirable optical properties (i.e.. high color intensity) to be suitable as sensors.
- Film quality, in this particular case color intensity was studied at different deposition pressures. It was found that films made at 40 mN/m gave the best transfer rate and color intensity. Therefore, the 1 : 1 NHS-PDA/PDA films obtained at this transfer pressure were selected for modification w ith hexokinase.
- Yeast hexokinase suspension (E.C. 2.7.1.1. from Boehringer Mannheim GmbH. Germany) was spun in a microcentrifuge to remove saturated ammonium sulfate. The protein was resolubilized in 0.1 M phosphate buffer (pH 8.0) to give approximately 1 mg/ml concentration, and dialyzed against the same buffer using a Slide-A-Lyzer dialysis cassette (Pierce) for 3 hours. The PDA monolayer slides were cut into 0.7 cm x 2.5 cm rectangular pieces, and incubated in the hexokinase solution at 4°C for 1 hr.
- diacetylene was first filtered to remove the insoluble impurities (e.g.. polymerized form) and converted chemically to NHS-PDA as described above.
- Appropriate amounts of NHS-PDA and other forms of PDA derivatives (e.g. , dopants or ligands) were mixed to give the desired molar ratio.
- the solution was dried using N 2 gas, so a thin layer of white material deposited on the bottom of the vial.
- Deionized water was added to bring the total concentration of lipid to approximately 1 mM.
- the solution was sonicated by using either a probe sonicator for approximately 20 minutes or a bath sonicator for over 2 hours until a clear solution was obtained.
- the solution was filtered through 5 ⁇ m filter while hot. then stored at 4°C overnight.
- Antibodies can also be attached to biopolymeric material by hydrazides. In some embodiments, this may be preferred to NHS-coupling because NHS may react at the Fab ' region of the antibody, blocking binding to analytes.
- the hydrazide method causes attachment of the Fc region of the antibodies to the biopolymeric material, leaving available, the binding region. In the hydrazide method. hydrazide-PDA lipids were produced, and unpolymerized liposomes are generated (e.g. , 20%o hydrazide PDA/80%) TRCDA).
- Uncoupled antibodies are removed from the liposomes by using Centricon 500 filters and washing with 900 ⁇ l Tris buffer (pH 9.0) and centrifugation at 4000 rpm for 2 minutes. After multiple washes, the sample is dilute (if necessary) with Tris buffer to make a 0.2 mM (or less) liposome solution.
- Example 7 The generation of PDA-linked ligands containing a variety of different chemical head-group species is described in Example 7, for VOC detection. These examples demonstrate the derivation of PDA with a broad range of chemical head groups such as hydrophilic uncharged hydroxyl groups, primary amine functionalities, amino acid derivatives, and hydrophobic groups. These and other modifications are generated by synthesis methods known in the art.
- various other surfactant-linked ligands can be prepared using condensation reactions involving an activated carboxylic acid group and a nucleophilic amino or hydroxy .
- PDA can be activated with trimethylacetylchloride under anhydrous conditions to form an active asymmetric anhydride.
- the anhydride can be treated with excess ethylene diamine or ethanolamine to form ethylenediamino-PDA (EDA-PDA) or ethanolamine-PDA (EA-PDA). respectively.
- EDA-PDA ethylenediamino-PDA
- EA-PDA ethanolamine-PDA
- One and a half mole equivalents of triethylamine are added as a catalytic base and reactions are allowed to proceed for three hours at room temperature.
- EDA-PDA and EA-PDA are chromatographically purified using a silica gel column and a chloroform/methanol gradient.
- the EDA-PDA or EA- PDA are then be condensed with free carboxylic acid containing ligands (chemically activated as above) to form the ligand-linked polymerizable surfactants.
- ligands that can be prepared by this method include, but are not limited to, carbohydrates, nucleotides. and biotin.
- the art contains numerous other examples of successful linkage or association of molecules to lipids and membranes.
- the self-assembling monomers associated with ligands can be of modified chain length or may consist of double or multiple chains.
- mixed liposomes (0.1 mM) composed of 95% PDA and 5% PDA-NH-NH-, were polymerized with 0.3 J cm "2 . These liposomes posses the same polymerization behavior as pure PDA liposomes and could be easily used for binding studies with keto-modified cells, aldehydes, ketones or NHS-esters. Although an understanding of the mechanism is not necessary to practice the present invention, and the present invention is not limited to any particular mechanism, liposomes made from pure PDA-NH-NH2 surprisingly did not polymerize in pure H 2 0.
- the colorimetric changes of the biopolymeric materials of the present invention are detected though simple observation by the human eye. Because of the simplicity of the observation, this function can be accomplished by an untrained observer such as an at-home user.
- This Example provides a description of the methods used in the development of the colorimetric analyses of the present invention.
- Spectroscopy means may be applied to acquire such data. Visible absorption studies were performed using a Hewlett Packard 8452A Diode array spectrophotometer. For PDA material (i.e. , films and liposomes). the colorimetric response (CR) was quantified by measuring the percent change in the absorption at 626 nm (i.e.. which imparts the blue color to the material) relative to the total absorption maxima. In order to quantify the response of a biopolymeric material to a given amount of analyte, the visible absorption spectrum of the biopolymeric material without the analyte was analyzed as
- B 0 is defined as the intensity of absorption at 626 nm divided by the sum of the absorption intensities at 536 and 626 nm.
- B a represents the new ratio of absorbance intensities after incubation with the analyte.
- the colorimetric response (CR) of a liposome solution is defined as the percentage change in B upon exposure to analyte.
- EXAMPLE 7 Detection of Analytes
- Analytes range from complex biological organisms (e.g.. viruses, bacteria, and parasites) to simple, small organic molecules (e.g.. alcohols and sugars).
- complex biological organisms e.g.. viruses, bacteria, and parasites
- simple, small organic molecules e.g.. alcohols and sugars.
- Specific applications of the present invention are described below to illustrate the broad applicability of the invention to a range of analyte detection systems and to demonstrate its specificity, and ease of use. These examples are intended to merely illustrate the broad applicability of the present invention. It is not intended that the present invention be limited to these particular embodiments.
- the present invention provides superior means of detecting influenza compared to currently available technology. Immunological assays are limited because of the antigenic shift and drift exhibited by the virus. The present invention detects all varieties of influenza and thus a determination of a patient's exposure to influenza will be definitive, and not limited to a particular strain. Indeed, even newly evolved, uncharacterized influenza strains can be detected.
- Sialic acid-linked biopolymeric material was generated as described in Examples 1 and 5. The materials were exposed to influenza virus and colorimetric information was observed visually or with spectroscopy as described in Example 6, and shown in Figure 27 for blue (solid line) and red phase (dashed line) material, respectively.
- a 1- 10% mixture of sialic acid-linked PCA was incorporated, as previous studies indicated that optimum viral binding occurs for mixtures of 1 -10% in liposomes (Spevak et al , J. Am. Chem. Soc. 161 : 1 146 [1993]).
- influenza virus detection system include additional ligands that recognize and differentiate influenza strains or serotypes from one another and from other pathogens.
- sialic-acid containing biopolymeric materials of the present invention provide means of detecting many other pathogens.
- sialic acid has the capability of detecting other analytes including, but not limited to, HIV, chlamydia, reovirus. Streptococcus suis. Salmonella, Sendai virus, mumps, newcastle, myxovirus, and Neisseria meningitidi .
- Cholera toxin is an endotoxin of the Gram-negative bacterium Vibrio cholerae that causes potentially lethal diarrheal disease in man. Cholera toxin is composed of two subunits: A (27 kDa) and B (1 1.6 kDa) with the stoichiometry AB The B components bind specifically to G M , gangliosides on cell surfaces, ultimately leading to translocation of the A, fragment through the membrane.
- Cholera toxin can be recognized by G M1 - containing supported lipid membranes and polymerized Langmuir-Blodgett films containing G M] and a carbohydrate "promoter" lipid (i.e., sialic acid-derived diacetylenes) as shown by Pan and Charych (Langmuir 13: 1365 [1997]).
- G M1 - containing supported lipid membranes and polymerized Langmuir-Blodgett films containing G M] and a carbohydrate "promoter" lipid i.e., sialic acid-derived diacetylenes
- Ganglioside G M1 cholera toxin from Vibrio Cholerae, human serum albumin, and wheat germ agglutinin were purchased from Sigma. 5,7-docosadiynoic acid was synthesized. Deionized water was obtained by passing distilled water through a Millipore ⁇ F ultrapurification train. Solvents used were reagent grade. The ganglioside G M] was mixed at 5 mol % with the diacetylene "matrix lipid" monomers. Liposomes were prepared using the probe sonication method and polymerized by UV irradiation (254 nm). The conjugated ene-yne backbone of polydiacetylene liposomes results in the appearance of a deep blue'purple solution. The visible absorption spectrum of the freshly prepared purple liposomes is shown in Figure 25.
- cholera toxin was diluted to 1 mg/ml in 50 mM Tris buffer. pH 7.0.
- blue phase liposomes produced as above were diluted 1 :5 in 50 mM Tris buffer, pH 7.0.
- the liposomes were pre-incubated in the buffer for 15-30 minutes to ensure stability of the blue phase prior to the addition of cholera toxin. No color changes were observed during this period.
- Cholera toxin was added to the cuvette by the method of successive additions. After each addition, the contents were mixed and the visible absorption spectrum was recorded as a function of time.
- Liposomes were prepared with 5% by mole of G M ] and 95% 5,7-DCDA.
- E. coli toxin (Sigma) was spun through a 30 K molecular weight cutoff filter at 2000 x g at 15°C to remove salts. The protein was re-diluted in 50 mM Tris buffer pH 7.0 to a final concentration of 1 mg/ml.
- Figure 29 shows the visible absorption spectrum of the polymeric liposomes containing 5% G, ,, ligand and 95%) 5,7-DCDA prior to exposure to E. coli toxin.
- the liposomes were diluted in 50 mM Tris buffer. pH 8.0 to a final concentration of 0.2 mM in a plastic disposable cuvette. The solution in the cuvette appeared purple to the naked eye.
- the present invention may also be used to detect a variety of other pathogens.
- Ligands specific for a large number of pathogens (e.g., carbohydrates, proteins, and antibodies) can be incorporated into the biopolymeric material using routine chemical synthesis methods described above and known in the art. Some of the examples of pathogen detection systems are presented below to demonstrate the variety of methods that can be applied using the present invention and to demonstrate the broad detecting capabilities of single ligand species (e.g., sialic acid).
- pathogens e.g., carbohydrates, proteins, and antibodies
- the sialic acid derivated material of the present invention has been used to detect the presence of parasites such as Plasmodium (i.e., the etiologic agent that causes malaria).
- the genetically conserved host binding site was utilized.
- PDA films containing sialic acid as described above were exposed to solutions containing malaria parasites and erythrocytes. After overnight exposure to the parasites, the films became pink in color. The color response (CR) in each case was nearly 100%o.
- the system be used in conjunction with other testing material (e.g.. arrays of biopolymeric material with various ligands) to identify and differentiate the presence of particularly virulent species or strains of Plasmodium (e.g., P. falciparum) or other pathogens.
- VOCs Volatile Organic Chemicals
- Certain embodiments of the present invention provide means to colorimetrically detect volatile organic compounds (VOCs).
- VOCs volatile organic compounds
- Most of the current methods of VOC detection require that samples be taken to laboratory facilities where they are analyzed by gas chromatography/mass spectroscopy.
- Some of the on-site methodologies require large, bulky pieces of equipment such as that used in spectroscopic analysis. While these methods are excellent for providing quantitation and identification of the contaminant, they cannot ensure the safety of the individual worker.
- the present invention provides a badge containing immobilized biopolymeric material that signals the presence of harmful VOCs and provides maximum workplace safety within areas that contain VOCs.
- the badge is easy and simple to read and requires no expertise to analyze on the part of the wearer.
- the color change of the badge signals the individual to take appropriate action.
- the badges reduce costs and improve the efficiency of environmental management and restoration actions, significantly reducing down-time due to worker illness by preventing over-exposure to potentially harmful substances.
- These sensors such as the quartz crystal microbalance (QCM) and the surface acoustic wave (SAW) devices (See e.g. , Rose-Pehrsson et al , Anal. Chem. 60: 2801 [1988] ). have linear frequency changes with applied mass.
- QCM quartz crystal microbalance
- SAW surface acoustic wave
- a sensor based on the QCM or SAW is constructed.
- the complex electronics involved in the use of SAW, QCM, and electrode based systems makes these approaches less amenable to use as personal safety devices.
- the present invention differs from these methods in that signal transduction is an integral part of the organic layer structure rather than signal transduction to an electronic device.
- embodiments of the present invention facilitate optical detection of the signal rather than electronic detection.
- the present invention provides flexibility in material design, allowing easy immobilization into a small cartridge (e.g.. a badge) rather than being burdened with the need for electronic equipment.
- FIG 31 shows the absorption spectrum of a PCA film in blue phase.
- the film changes to red phase PCA, curve b, upon exposure to approximately 500 ppm of 1 -octanol dissolved in water.
- the degree of color change was generally dependent upon the concentration of the solvent and also increased with the extent of halogenation and aromaticity.
- a single component thin membrane film of PCA was prepared and polymerized to the blue state by UV exposure (254 nm).
- the y-axis represents the colorimetric response, or the extent of blue-to-red conversion.
- the numbers above the bar represent an upper limit to the detection in ppm. For many of these solvents, it is clear that solvent concentrations well below 500 ppm can be detected.
- the pharmaceutical industry has an ongoing need for solvent sensors, as pharmaceutical compounds are typically manufactured through organic chemical reactions that take place in the presence of solvents.
- the solvent Before packaging of a drug for use in humans or other animals, the solvent must be completely driven off (Carey and Kowalski, Anal. Chem. 60: 541 [1988]).
- the currently used method for detecting these VOCs uses energy- intensive dryers to blow hot air across the drug and piezoelectric crystal arrays to analyze the evaporation of the various solvents (Carey, Trends in Anal. Chem. 13: 210 [1993]).
- the present invention provides a colorimetric based approach that greatly simplify these measurements.
- the purpose of this example is to show the development of a new class of functional materials that specifically trap small organic compounds and report the entrapment event by a colorimetric change which can be detected visually. These material act as simple color-based sensor devices that detects the presence of compounds such as solvents or other toxic pollutants in air or water streams.
- the first step involves the synthesis of lipid diacetylene analogs of compounds 1 and 2 as shown in Figure 34.
- the enantiometrically pure ester of PDA (pentacosadiynoic acid) 3 is hydroxylated via molybdenum peroxide oxidation to alcohol 4.
- Diasteriomers are separated and the ester is hydrolyzed to chiral lactate analogs 5 and 6.
- the ethyl esters are formed and treated with Grignard reagents to give the desired chiral lipid analogs 7 and 8. Variation in the R groups result in a wide variety of new materials in which the specific entrapment capabilities are reviewed.
- the monomer-lipid clathrate is ordered and compressed on the water surface using a Langmuir-Blodgett film apparatus. Polymerization of the monolayer by UV irradiation yields the blue colored material as described above. The film is lifted onto a hydrophobized microscope slide. Exposure of these materials to analytes (e.g. , 1-butanol or dioxane) produces a colorimetric response.
- analytes e.g. , 1-butanol or dioxane
- the hexokinase modified films were placed onto silanized glass cover slides for the purpose of measuring the optical properties.
- the biosensor coated glass cover slides were placed in glass cuvettes and the UV-Vis spectra of hexokinase modified films were recorded in 0.1 M phosphate buffer (pH 6.5). Measurements taken in this buffer condition were considered background. Addition of glucose, or other sugar substitutes, occurred directly in the cuvettes.
- the materials of the present invention comprise nucleic acid ligands that allow specific detection of DNA hybridization or other nucleic acid interactions via nucleic acid molecular recgnition of a single stranded sample DNA (ss-s- DNA) with single stranded probe DNA (ss-p-DNA), which is covalently attached to the surface of the biopolymeric material of the present invention.
- ss-s- DNA single stranded sample DNA
- ss-p-DNA single stranded probe DNA
- analytes detectable by the present invention demonstrate the broad range of analytes detectable by the present invention, ranging from complex biological organisms (e.g. , viruses, bacteria, and parasites) to simple, small organic molecules (e.g. , alcohols).
- complex biological organisms e.g. , viruses, bacteria, and parasites
- simple, small organic molecules e.g. , alcohols.
- ligands linked to biopolymeric material including, but not limited to botulinum neurotoxin detected with ganglioside incorporated PDA (Pan and Charych, Langmuir 13: 1367 [1997]). It is contemplated that numerous ligand types will be linked to self-assembling monomers using standard chemical synthesis techniques known in the art to detect a broad range of analytes.
- ligand types can be incorporated into the biopolymeric matrix without covalent attachment to self-assembling monomer. These materials allow for the detection of small molecules, pathogens, bacteria, membrane receptors, membrane fragments, volatile organic compounds, enzymes, drugs, and many other relevant materials.
- the present invention also finds use as a sensor in a variety of other applications.
- the color transition of PDA materials is affected by changes in temperature and pH.
- the methods and compositions of the present invention find use as temperature and pH detectors.
- Ligands can also be used in the present invention when they function as competitive binders to the analyte. For example, by measuring the colorimetric response to an analyte in the presence of a natural receptor for the analyte, one can determine the quantity and/or binding affinity of the natural receptor.
- Competition or inhibition techniques allow the testing of very small, largely unreactive compounds, as well as substances present in very low concentrations or substances that have a small number or single valiancy.
- One application of this technique finds use as a means for the development and improvement of drugs by providing a screening assay to observe competitive inhibition of natural binding events.
- the compositions of the present invention further provide means for testing libraries of materials, as the binding of desired material can be colorimetrically observed and the relevant biopolymeric material with its relevant ligand separated from the others by segregating out a particular polymeric structure.
- the silicon gel or wafers are acid cleaned in 1 : 1 HCl/mefhanol, rinsed in water, and placed in concentrated sulfuric acid. After a thorough water rinse, the wafer chips or gel is boiled in doubly distilled deionized water, allowed to cool and dry and then silanized under inert atmosphere in a 2% solution of 3-mercaptopropyl trimethoxysilane prepared in dry toluene.
- the chips or gels are placed in a 2 mM solution of either GMBS (N-succinimidyl 4-maleimidobutyrate) or EMCS (N-succinimidyl 6- maleimidocaproate) prepared in 0.1 M phosphate buffer (the cross linker is first dissolved in a minimal amount of dimethylformamide). After rinsing with phosphate buffer, the chips are placed in a 0.05 mg/ml solution of the liposomes prepared in pH 8.0 phosphate buffer. Finally-, the chips or gels are thoroughly rinsed with, and then stored in, the buffer solution prior to their use.
- the liposomes should have an -NH 2 functionality for the cross- linking with GMBS or EMCS to work.
- a silica sol was prepared by sonicating 15.25 g of tetramethylorthosilicate (TMOS). 3.35 g of water, and 0.22 ml of 0.04 N aqueous hydrochloric acid in a chilled bath until the solution was one phase (approximately 20 minutes). Chilled MOPS buffer solution (50% v v) was then added to the acidic sol making sure that the solution was well cooled in an ice bath to retard gelation.
- TMOS tetramethylorthosilicate
- TEOS tetraethylorthosilicate
- methyltriethoxysilane (MeTEOS), aryl silsesquioxanes, and other metal oxides find use in generating sol-gel glass.
- a polymerized liposome solution (2.5 ml) (as generated in Example 1) was then mixed into the buffered sol (10 ml) and the mixture poured into plastic cuvettes, applied as a film on a flat surface, or poured into any other desired formation template, sealed with Parafilm, and allowed to gel at ambient temperature.
- biopolymeric material shapes i.e., film and other nanostructures
- the materials must be generated or sectioned into small (i.e., nanoscopic) sized portions if not already so, and incorporated into a solution to be mixed with the buffered sol.
- the present invention contemplates the generation of a large palette of polymerizable lipids of different headgroup chemistries to create an array.
- Lipids containing head groups with carboxylic acid functionalities (imparting a formal negative charge), hydrophilic uncharged hydroxy groups, primary amine functionalities (that may acquire a formal positive charge), amino derivatives (with positive, negative or zwitterionic charge), and hydrophobic groups among others can be generated.
- the combination of these materials into a single device facilitates the simultaneous detection of a variety of analytes or the discrimination of a desired analytes from background interferants.
- biopolymeric materials comprising varying dopant materials are used to provide a different color pattern for each portion of the array.
- a large palette of polymerizable lipids of different headgroup chemistries can be generated to create an array.
- Figure 37 depicts lipids with various head group chemistries. These may be categorized into five groups based upon their head group functionality.
- Compounds 2.4 and 2.5 contain carboxylic acid functionalities, imparting a formal negative charge.
- Compounds 2.6 and 2.7 contain a hydrophilic uncharged hydroxyl group.
- Compounds 2.8 and 2.9 have primary amine functionalities that may acquire a formal positive charge.
- the amino acid derivative 2.10 may exist with positive, negative or zwitterionic charge.
- Compounds 2.11-2.13 have hydrophobic head groups.
- the synthesis of these lipids begins with commercially available PDA (2.4). Synthesis of all but 2.10, 2.12, and 2.13 can be carried out by coupling the respective head group to PDA utilizing the activated N-hyroxysuccinimidyl ester of PDA (NHS-PDA) as described above.
- the amino acid lipid 2.10 can be prepared in four steps from PDA as shown in Figure 38. using lithium aluminum hydride and transformation of the alcohol to the corresponding bromide derivative. The bromide is converted to the protected amino acid by reaction with diethyl N-acetimidomalonate in acetonitrile with sodium hydride, followed by deprotection.
- the fluorinated lipids 2.12 and 2.13 can be prepared by the reaction of pentafluorobenzoyl chloride with amino lipids 2.8 and 2.9.
- Materials prepared as above can be deposited into chambers of a device or immobilized to specific portions of a device.
- a single apparatus e.g., a badge
- an array is generated with the ability to identify, distinguish, and quantitate a broad range of reactions and analytes.
- the construction of a patterned DNA assay automated DNA synthesis is carried out with the growing chain linked to the polydiacetylene bilayer system on solid substrates, as shown in Figure 46.
- the activated nucleotide monomers which are added in each cycle carry a photosensitive protecting group at the 5 " end. After the coupling reaction, the chain ends (5') are capped with the photosensitive protecting group.
- the photosensitive protecting group By irradiation of the substrate through a mask, only the parts of the substrate that are irradiated are deprotected.
- a single substrate (detector) surface several independent ss-p-DNA sequences can be synthesized in a parallel manner by appropriate choice of masks.
- the method requires a photosensitive protecting group that is cleaved at a wavelength which does not affect the DNA itself ( ⁇ abs - 260 nm) or interfere with the polydiacetylene backbone.
- photosensitive protecting groups are o-nitrobenzlyoxy esters of phosphoric acid ( ⁇ ab « 340 nm) and related compounds (See. Greene et al, Protective Groups in Organic Synthesis, second ed.. John
- Biopolymeric liposomes were prepared by probe sonication of a mixture of polymerizable matrix lipid 10,12-tricosadiynoic acid and various mole fractions (0%-40%) of PLA 2 substrate lipid (e.g.. DMPC) in water, followed by polymerization with 1.6 ⁇ J/cnr ultraviolet radiation. 254 nm. Analysis by transmission electron microscopy- indicated an average vesicle size of approximately 100 nm.
- PLA 2 substrate lipid e.g.. DMPC
- Spectrophotometer Model 9153C Bee venom phospholipase A 2 (Sigma) was dissolved in a 10 mM Tris. 150 mM NaCl, 5 mM CaCl 2 buffer pH 8.9 to yield a final concentration of 1.4 mg/ml PLA 2 . 50 ⁇ l of this solution was added to the cuvette and the spectrum was recorded after 60 minutes. Upon addition of PLA 2 to the DMPC/PDA vesicles, the suspension rapidly turned red (i.e., within minutes) and exhibited a maximum absorption at approximately 540 nm as shown in Figure 13, described above.
- Liposomes containing a range of mole% DMPC were tested for their ability to produce a colorimetric response.
- Five microliters of 1.4 mg/ml PLA 2 was added to 50 ⁇ l of DMPC/PDA vesicles (0.1 mM final total lipid concentration).
- the experiment was carried out in a standard 96-well plate using a Molecular Devices UV Max kinetic microplate reader.
- the absorption of the vesicle solution was monitored as a function of time at 620 nm and 490 nm wavelengths.
- the data was then plotted as colorimetric response (CR) -v ersus time to yield the color response curves as shown in Figure 17. described above.
- CR colorimetric response
- PLAn activity was independently measured using a labeled lipid analog incorporated into the PDA matrix, allowing simultaneous measurement of product formation and colorimetric response of the vesicles.
- the analog used was thioester 1.2-bis-(S-decanoyl)- l ,2-dithio-sn-glycero-3-phosphocholine (DTPC).
- DTPC thioester 1.2-bis-(S-decanoyl)- l ,2-dithio-sn-glycero-3-phosphocholine
- NMR experiments were conducted to further verify the occurrence of interfacial catalysis by PLA : . and provide information of the fate of the enzymatic reaction products.
- the spectra were taken at a magnetic field of 1 1.7 Tesla on a Bruker DMX500 NMR spectrometer.
- the Block-decay pulse sequence was used with 2048 acquisition data points. 40 000 free induction decays were accumulated in each experiment with 2 second recycle delays. 0.1 M phosphoric acid was used as an external reference.
- Figure 16 shows the 3 I P NMR spectra of A) Mixed DMPC/PDA vesicles, 0.1 mM total lipid; B) the same vesicle suspension after addition of PLA 2 (200 ng).
- the assays for phospholipase D and C were run under similar conditions as the phospholipase PLA. assays. In all assays, 1 mM 40%> DMPC/ 60%> 10,12-tricosadiynoic acid (TRCDA) liposomes were used. Aqueous stock solutions of phospholipase D and C were prepared by dissolving the enzymes at 1 mg/ml concentration in 50 mM Tris. 150 mM NaCl. 5 mM CaCl 2 pH 8.9 buffer and 20 mM sodium borate, 150 mM NaCl. 5 mM CaCl 2 pFI 8.9 buffer, respectively. The assays were then performed by adding 5 ⁇ l of liposomes. 45 ⁇ l 50 mM Tris pH 7.0 (or 20 mM sodium borate pH 7.0 when testing
- Inhibitors were used to block the colorimetric event initiated by PLA 2 .
- DMPC/PDA vesicles containing 0.6% MJ33 were polymerized and incubated with 5 ⁇ l of 1.4 mg/ml PLA ; .
- Five microliters of unpolymerized liposomes were combined with 40 ⁇ l of 50 mM Tris pH 7.0, 5 ⁇ l MJ33 (0.006 M dissolved in water), 5 ⁇ l of 50 mM Tris, 150 mM NaCl. 5 mM CaCl 2 pH 8.9. and incubated for 15 minutes.
- the liposomes were then polymerized in 96 well plates and absorption spectrum were recorded at 490 nm and 620 nm.
- Five microliters of PLA. were added and spectra at specific time intervals were monitored for one hour.
- the enzyme was dissolved in 10 mM Tris, 150 mM NaCl. 0.1 mM ZnCl 2 pH 8.9.
- oligonucleotides were derivatized to form single stranded probe DNA (ss-p-DNA) for incorporation into biopolymeric liposomes.
- the liposomes were prepared from a lipid mixture of 95% compound 1 ( Figure 41 ) and 5% compound 3 ( Figure 41). as described above by sonicating a dried film of the lipid mixture in an aqueous medium. This liposome solution was photopolymerized by irradiation with UV light (254 nm). and then either compound 4 ( Figure 41 ; [SEQ ID NO:2]) or compound 5 ( Figure 41) was added to form covalent linkages at the active ester lipid sites of compound 3. This process is illustrated in Figure 42.
- Coupling the ⁇ , ⁇ -bisamino ss-p-DNA (i.e.. compound 5) to the surface of the polymeric liposome potentially creates a more sensitive probe than one generated with compound 4.
- the single stranded DNA forms a coiled structure in solution as known from dissolved polymers. Attaching the coiled ss-p-DNA. compound 5. to the liposome surface resulted in two relatively close linkages. Upon hy bridization the double helical DNA elongates and causes, simultaneously- at both linkages, conformational changes in the polydiacetylene backbone. This cooperative effect increases the sensitivity of colorimetric detection.
- the characteristics of these liposomes can be determined from various measurements, including TEM (e.g.. freeze fracture method) and light scattering.
- Raman- and UV/Vis spectroscopy give information about the polymer backbone, whereas FTIR spectroscopy is sensitive for the alkyl chains.
- Surface topology is revealed under the AFM. and the chemical composition of the surface may be probed by XPS. although the present invention does not require such characterization experiments.
- Compound 1 and analogues 2 and 3 of Figure 41 were used and derivatized to yield the desired functionalizations at the membrane surfaces.
- Figure 41 shows the film structure with the conjugated polymer backbone before and after photopolymerization with lipid 1.
- the oligonucleotide dGGGAATTCGT (SEQ ID NO:4). complementary to a sequence on the Ml 3 phage DNA. could be derivatized to form the ss-p-DNA compounds 4 and 5. which carry amino groups at the chain ends. These amino groups can react with the active ester lipid. compound 3. in a polydiacetylene film, allowing the attachment of the ss-p-DNA to the liposome or bilayer after photopolymerization.
- the present invention be limited to any particular ss-p-DNA sequences.
- the ODN-lipid conjugate Oligo 1 (hereinafter. "W001 ") was obtained by reaction of NHS-PDA with the amino functionalized 27-mer Oligo 1 in DMSO / aqueous buffer medium (pH 9, Na 2 C0 3 /NaHC0 3 buffer, 0.1 M) as shown in Figure 45.
- the NHS-PDA dissolved in DMSO partially crashed out of solution when added to the aqueous ODN-buffer solution, but nevertheless the reaction proceeded over a period of two weeks in the cold (i.e., approximately 4°C).
- a second attempt to form the amide in a two-phase system i.e.
- the primary OH-group of the 5 " -terminus was conjugated to a diacetylene lipid with phosphate head group, using DCC as condensation agent and pyridine as base as shown in Figure 43.
- the lipid was coupled to the detritylated Oligo 2 (i.e.. the lipid-linked oligonucleotide designated as seq.l-DA13//90P03H2 in Figure 43) carrying the nucleobase protecting groups and which was bound to the solid support.
- the ODN-lipid conjugate was cleaved from the solid support and deprotected with the standard NH, workup to y ield Oligo 2 conjugate. Large batches of liposomes were prepared during these experiments.
- Lipids were inially filtered, and the filtered lipid solution was placed in organic solvent.
- the total volume of organic solvent in a liposome solution with a volume of 30-80 ml was less than 5 ml, giving a high concentration of the lipid.
- the beaker was placed onto a handwarm heat plate and a gentle stream of N 2 was passed over the surface of the liquid. After complete evaporation a magnetic stirrbar and the appropriate ammount of H 2 0 was added. The beaker was then mounted in the sonicator chamber on top of a magnetic stirrer with the sonicator tip resting 1 -2 mm above the stirrbar.
- the liquid was sonicated at 60% output power. with gentle stirring and heating (i.e. , with a heat gun) until all solid was dispersed. After the appropriate sonication time (5-30 min) the hot solution was filtered through a 0.8 ⁇ m Metricel filter and refrigerated.
- ODN lipid-linked oligonucleotide
- SEQ. 1 the lipid-linked oligonucleotide designated as seq. l-DA13//90P03H2 in Figure 43.
- photopolymerized 1.6 J cm "2
- cc30 filtration the filters used were centricon 30 filters with a molecular cutoff at -30 000 g mol " ' and filtration was achieved by centrifugation), the amount of ODN associated with the liposome phase was drastically reduced and the filtrate contained most of the ODN. After a second filtration step, most of the ODN was removed from the liposome phase. The loss of liposomes by 10-15% due to the filtration procedure, was comparable to that observed using pure liposomes. ODN loss by cc30 filtration was quantified by subtracting the liposome background from the UV-Vis spectra, to obtain the pure ODN absorbance, reflecting a direct measure of ODN concentration in the liposome phase.
- ODN concentration in the retained liposome phase depended on three major factors: i) the dilution of the remaining ODN in the retentate which was diluted following an exponentially declining function: ii) a fraction of the ODN unspecifically bound to the liposomes, with binding in equilibrium with the ODN concentration in the surrounding medium; and iii) the loss of ODN by absorption of liposomes at the filter surface by which ODN gets entrapped in the filter and which was correlated to polymer loss.
- the last factor becomes particularly- important when the ODN is specifically bound to the liposome surface, as is the case with the ODN-lipid conjugates.
- PDA liposomes (1 mM concentration) were mixed with 5% "Oligo 3" (SEQ ID NO:3) (the complement of Oligo 2). The liposomes precipitated upon irradiation, which was due to the high salt content in this ODN sample.
- the PDA liposomes were diluted to a concentration of 0.1 mM prior to polymerization. After incubating the diluted liposomes with 5% Oligo 2 for 14 h at room temperature and 6 h at 4°C, photopolymerization was achieved with an energy dose as low as 0.3 J cm '2 (254 nm) in a comparable yield to pure PDA liposomes.
- EDC EDC
- NHS NHS
- prepolymerized PDA liposomes (0.1 mM) / Oligo 1 (5%) were used. Unpolymerized PDA liposomes (0.1 mM) were cc30 filtered once, rediluted and polymerized (0.3 J cm "2 ) and then incubated with 5% Oligo 1 for 11 h at room temperature. After ODN incubation, the liposomes were filtered twice more, with a polymer loss of 17% per filtration step. In yet other experiments, prepolymerized PDA liposomes (0.1 mM) / Oligo 1 (5%>) were used with EDC and NHS-treated.
- EDC and NHS were added to the liposome surface, and the liposomes were polymerized before incubation with ODN.
- the PDA liposomes were filtered once in monomeric form, rediluted to 0.1 mM, polymerized (0.3 J cm "2 ) and incubated with 5%> Oligo 1 , EDC (50 ⁇ l of 0.6 mg ml " ' EDC HCl in H 2 0) and NHS (1 ⁇ l of 0.6 mg ml " ' NHS in H 2 0) for 1 1 h at room temperature. After incubation, the ODN-liposome mixture was filtered a second and a third time with a linear polymer loss of 15% and 23%o, respectively.
- liposomes were investigated for their ability to covalently bind amino functionalized Oligo 1 on their surface.
- the polymerized liposomes (0.3 J cm “2 . 0.1 mM) were incubated with 5% Oligo 1 for 1 1 h at RT, cc30 filtered, and rediluted to the original volume. The cc30 filtration was repeated two more times, and the polymer loss was measured at 640 nm, showing a slight exponential "flattening out.”
- the ODN retention was also a function of polymer loss, as ODN is extracted from solution with filter-adsorbed liposomes. This fact complicated the determination of actual ODN concentration relative to liposome concentration, since the precise nature and extent of ODN-liposome interaction was not known. Generally, the relative ODN retention in terms of liposome concentration was higher than the absolute ODN retention (i.e., relative to the total volume of the liposome phase).
- PDA liposomes (0.1 mM) were incubated with 5% Oligo 4 followed by polymerization (0.3 J cm “2 ), and filtered to give a polymer retention of 39% and an ODN retention of 31%) ( Figure 27).
- POS liposomes (0.1 mM) made from the monophosphate 10.12-hexacosadiyn-l-ol phosphate (hereinafter, "DA 13 liposomes”) were incubated with 5% of Oligo 2 lipid. which were then polymerized (0.3 J cm "2 ), and three times cc30 filtered with a 51% polymer retention.
- SEQ ID NOT (Oligo 2: SEQ1) ( 5' GGG AAT TCG T- r ) and SEQ ID NO:2 (Oligo 3; SEQ2) ( 5 ACG AAT TCC C 3' ) were synthesized on an Experdite 8909 nucleic acid synthesis system (PerSeptive Biosystems) by the standard phosphoramidite route.
- the general phosphoramidite method is schematically depicted in Figure 46.
- a first step A the dimethoxytrityl (DMT) group was cleaved at the 5 '-end of a solid support bound nucleotide.
- the solid support was usually controlled pore glass (CPG) which was modified with long chain alkylamino groups to which the nucleotide was bound at the 3 " -end of the deoxyribose via a succinvl spacer.
- CPG controlled pore glass
- the free 5'-OH group was then activated in step B) by tetrazole and coupled with a phosphoramidite, to form the one nucleotide elongated chain.
- step C the dimethoxytrityl
- the unreacted 5 ' -OH ends was esterified with acetic anhydride to reduce the occurence of failure sequences.
- the phosphite triester bond was oxidized to the corresponding phosphotriester by iodine in pyridine/H-,0.
- the cycle was then repeated ad libidum with the needed phosphoramidites, until the final sequence is established.
- aqueous NH 3 (30%), cleavage from solid support, and deprotection of the nucleotides, free bioactive DNA was obtained. Removal of protecting groups, salt and small byproducts can usually be achieved by spin column chromatography through Sephadex G-25 or G-50 columns.
- Cleavage from CPG and deprotection of DNA may be achieved by a variety of methods.
- the column is cut open to retrieve CPG beads, which are transferred into a small screw-capped, teflon-lined container.
- the CPG beads are treated for 6-8 h at 55°C with 1 ml cone.
- NH 4 OH (30%) and ammonia is then decanted from the beads.
- NH 4 OFI (30%) are connected to the ends of the column, the ammonium hydroxide solution pushed forth and back for 1.5 h. transferred to a glass vial and heated for 6 h at 55°C.
- the DNA containing ammonium hydroxide solution is evaporated to dryness by centrifuging (i.e., "speed vac"), and the solid obtained is redissolved in 200 ⁇ l H 2 0.
- the free 5 ' -end of the fully protected and polymer support bound SEQ1 was treated with PDA and DCC at room temperature in CH,C1 2 to obtain the DNA-PDA conjugate.
- the side products i.e., dicylclohexyl urea
- excessive reagents can be washed from the column prior to DNA cleavage to avoid unnecessary purification steps.
- the reaction scheme for conjugation of SEQ1 with PDA is illustrated in Figure 47. Since DNA cleavage from polymer support and removal of protecting groups (benzoyl and wo-butyloyl groups) was achieved by treatment with concentrated ammonia solution (30%) at 55°C for 6-8 hours the danger of cleaving the DNA-PDA ester bond had to be considered.
- the gels were stained with ethidium bromide or silver nitrate, and showed that the 10-mers are very insensitive to ethidium bromide. Electrophoresis shows that SEQ1 samples ran slightly faster than SEQ2, and that SEQ1- PDA and SEQ2 formed hybrides that stained well with ethidium bromide.
- diacetylene lipids i.e. , phosphoramidites
- the stability of PDA against iodine in acetonitrile was tested by- dissolving PDA and I 2 in acetonitrile at room temperature, and conducting TLC after 5 min.
- the L was used as oxidizing agent in automated DNA synthesis to oxidize the trivalent phosphonium ester to the pentavalent phosphoric acid ester after the nucleobase coupling step ( Figure 33).
- Oligo 2 was conjugated with DAI 3 lipid.
- a 2 mM DAI 3 solution (2.5 mL. 5 ⁇ mol) in CH 2 C1 2 / EtOH (95:5) was rotavaped to dryness and redissolved in 1 ml CH 2 C1 2 and 1 ⁇ l pyridine.
- To this solution was added 5.2 mg (25 ⁇ mol) of DCC. and the mixture was injected into a membrane filter (MemSyn Nucleic Acid Synthesis Device, PerSeptive Biosystems) carrying the detritylated, fully protected Oligo 2. The reaction was left overnight while an insoluble white precipitate formed
- Oligo 1 was conjugate with NHS- PDA.
- a solution of NHS-PDA (6 ⁇ l , 0.24 mg. 508 nmol) NHS-PDA solution in CH 2 C1 (40 mg ml " ') was dried and redissolved in 90 ⁇ l DMSO. Then, 70 ⁇ l Oligo 1 (0.26 ⁇ mol ml " ') and 10 ⁇ l Na 2 C0 3 / NaHC0 3 buffer pH 9 (1 M) were added to the solution, causing the NHS-PDA to precipitate. The reaction mixture was kept at room temperature overnight and then stored for two weeks at approximately 4°C.
- the mixture was diluted with 1000 ⁇ l of H 2 0 and extracted five times with 500 ⁇ l CH 2 CL (each time).
- the aqueous phase was speedvaced and redissolved in 100 ⁇ l H 2 0 yielding the raw W001 (Oligo 1 conjugate) fraction (150.5 pmol ⁇ l " ', 1304 ⁇ g ml " ' ODN + NHS).
- the buffer solution was prepared by mixing aqueous solutions of Na 2 C0 3 (1 M) and NaHC0 3 (1 M) in a ratio of 1 :8.
- n-butanol Precipitation with n-butanol was accomplished by adding n-butanol (300 ⁇ l ) to -30 ⁇ l ODN solution. The solution was shaken well and centrifuged at 14000 rpm for 10 minutes. The organic phase was carefully decanted from the pellet. 300 ⁇ l ethanol (100%) was added and spun at 14000 rpm for 5 min.. After the ethanol was decanted, the pellet was dryed in the speed-vacuum for -1 minute.
- N-(6-aminohexyl)-p-azidobenzoic amido was synthesized.
- N- succinimidyl 4-azidobenzoate 250 mg. 0.95 mmol, ABA-NHS
- 2 ml CH 2 C1 2 water bath cooling
- a solution of 550 mg (4.8 mmol) hexamethylenediamine in 2 ml CH L was added.
- a white precipitate formed immediately and 4 ml CH 2 CL was added and stirred for 30 min..
- -5 ml H-,0 was added, upon which a stable emulsion formed.
- the organic phase was extracted several times with water, separated from the white solid at the interface and dried. This compound decomposes in solid form at -18°C over the period of several weeks, but it is stable in ethanolic solution (1 mM).
- the solution was concentrated again to 400 ⁇ l (via speed vac), and the DNA concentration was found to be 430 pmol ⁇ l "1 / 1314 ⁇ g ml " '.
- the SEQ2 solution was filtered through 1 ml Sephadex G-25 by spinning for 1 min at 1000 r min ' to obtain the fraction SEQ2 spin c.s.p.B. with a concentration of 221 pmol ⁇ l " ' / 673 ⁇ g ml " '.
- the column was spun dry for 2- min /1000 r min " '.
- PDA (7.4 mg, 20 ⁇ mole) was dissolved in 1 ml CH 2 C1 2 . filtered through a 0.22 ⁇ m Teflon membrane to remove polymerized material. To the filtered PDA was added dicyclohexylcarbodiimide (DCC. 4.1 mg. 20 ⁇ mole). The 0.2 ⁇ m column with detritylated SEQ1 was washed with 2 ml CH 2 C1 2 . and then the PDA reaction mixture was injected into the column containing SEQ1 by connecting two syringes at both ends of the column, and pushing the mixture several times back and forth.
- DCC dicyclohexylcarbodiimide
- the reaction was allowed to proceed overnight at room temperature.
- the reaction mixture was removed the following day, and the column was flushed with 2 mL portions of CH-,0, twice, followed by flushing with 2 mL portions of EtOH.
- 1 ml of cone. NH-. solution (30%) was injected and pushed forth and back several times over the period of 1.5 h. Due to a leak, 0.5 ml of the NH 3 solution was lost after 15 min reaction time. After 1.5 h the remaining solution was transferred to a vial with a teflon-lined screw cap, which was sealed and heated for 6 hours at 55°C. The solution was then transferred to an Eppendorf tube and concentrated to dryness in a speed-vac centrifuge.
- the solid was dissolved in 200 ⁇ l H 2 0 and divided into the following volumes: i) 50 ⁇ l SEQ1-PDA raw (433 pmol ⁇ l " ' / 1368 ⁇ g ml " '); and ii) 150 ⁇ l SEQ1-PDA raw-, with further addition of 50 ⁇ l TE, and desalted through Sephadex G-25 spin column (SEQ1-PDA s.c. 213 pmol ⁇ l " ' / 672 ⁇ g ml " '). Through the spin column another 200 ⁇ l TE was run to wash down remaining DNA (SEQ 1 -PDA s.c.(TE). 52 pmol ⁇ l "1 / 163 ⁇ g ml " ').
- the two complementary DNA strands i. e.. SEQ-PDA and SEQ2 are mixed at 1 ⁇ g (each) in 100 ⁇ l FLO, heated for -3 min in boiling water and slowly cooled.
- SEQ 1 -PDA raw 1368 ⁇ g ml " '
- 2 ⁇ l SEQ2 spin c.s.p.B (673 ⁇ g ml " ') were mixed together in 134 ⁇ l H 2 0. to give a final concentration of 10 ng ⁇ l "1 (HybA).
- the follow ing example illustrates the use of materials and methods of the present invention to detect target nucleic acid molecules in a sample suspected of containing nucleic acid associated with HIV-1.
- this example illustrates the use of the nucleic acid-linked biopolymeric materials of the present invention to detect the presence of HIV-1 in clinical samples using the methods of the present invention.
- the procedure described below is a modification of the reverse dot blot procedure described in U.S. Pat. 5.599.662 to Respess (herein incorporated by reference), used to detect HIV-1.
- nucleic acid linked biopolymeric materials of this Example are prepared according to Example 1 1. except a different nucleic acid ligand sequence (probe) is used.
- Clinical samples are obtained from subjects suspected of being infected with HIV-1 by taking a blood sample, and isolating the peripheral blood monocytes by the standard Ficoll-Hvpaque density gradient method described in Boyum (Boyum. Scan. J. Clin. Lab. Invest.. 21 (Suppl.97):77 [1968]; herein incorporated by reference).
- Another method involves isolating the white blood cells from the blood sample by direct red blood cell lysis and DNA extraction as described in Casareale et al, (Casareale et al, PCR Meth. Appln.. 2:149-153[1992]; herein incorporated by reference).
- the next step involves amplifying the target HIV-1 DNA which may be present in the clinical sample.
- the colorimetric materials and methods of the invention have many advantages for detecting the presence of DNA in a sample.
- this method allows the detection of amplified target DNA without the need to label the target DNA.
- This method also does not require a wash step, nor the addition of a developing solution (e.g.. avidin-HRP) in order to detect the presence of target DNA.
- a developing solution e.g. avidin-HRP
- This Example demonstrates the usefulness of the methods and materials of the present invention as applied to a home pregnancy test.
- this Example demonstrates the use of the nucleic acid-linked biopolymeric material of the present invention for the detection of human chorionic gonadotropin in urine for early pregnancy- diagnosis.
- Human chorionic gonadotropin is a glycoprotein hormone synthesized by the placenta and released in blood and urine soon after the implantation of a fertilized ovum in the chorionic tissue. As such, the detection of hCG is widely used as a pregnancy indicator in home pregnancy tests (See, U.S. Pat. 5,145,789, herein incorporated by reference).
- the nucleic acid linked biopolymeric materials of this Example are prepared according to Example 1 1. except a different nucleic acid ligand is used.
- the nucleic acid ligand in this Example must have affinity for hCG in order to be useful in a home pregnancy test.
- One method for identifying such nucleic acid ligands is the SELEX procedure described above. The basic SELEX procedure is described in U.S. Pat. Nos. 5.475,096: 5.270.163; and 5.475,096; and in PCT publications WO 97/38134, WO 98/33941. and WO 99/07724, all of which are herein incorporated by reference.
- the SELEX procedure allows identification of a nucleic acid molecules with unique sequences, each of which has the property of binding specifically to a desired target analyte or molecule.
- This procedure was used by Drolet et al (U.S. Pat. 5,874.218; herein incorporated by reference) in order to find a nucleic acid ligand that specifically bound to hCG.
- This nucleic acid sequence is called H-42 RNA by Drolet et al., and can be synthesized by the standard phosphramidite route as described in Example 1 1 , or isolated by employing the SELEX procedure.
- This hCG specific nucleic acid ligand is amino- functionalized and reacted with NHS-PDA as described in Example 1 1 in order to covalently link these sequences to the biopolymeric material of the present invention (i.e.. these sequence serve as the nucleic acid ligands of the present invention).
- This biopolymeric material is used to detect hCG for home pregnancy tests as described below.
- the biopolymeric material is then immobilized to a solid support, such as nylon filter paper, in order to construct a home pregnancy testing device.
- a solid support such as nylon filter paper
- the biopolymeric material of the present invention changes from one distinct color to another in the presence of urine or blood containing hCG.
- a feature of the present invention that provides various advantages (e.g., ease of reading), that are lacking in the Corti et al device.
- the presence of hCG is detected by hCG binding to the nucleic acid ligands linked to the biopolymeric material of the present invention which causes a color change in biopolymeric material.
- the present invention provides an easy to use device that is easy to read and analyze, suitable for point-of-care. and/or home testing.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Composite Materials (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9026698P | 1998-06-22 | 1998-06-22 | |
| US90266P | 1998-06-22 | ||
| PCT/US1999/014029 WO1999067423A1 (en) | 1998-06-22 | 1999-06-22 | Nucleic acid-coupled colorimetric analyte detectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1112377A1 EP1112377A1 (de) | 2001-07-04 |
| EP1112377A4 true EP1112377A4 (de) | 2004-11-10 |
Family
ID=22222032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99930522A Withdrawn EP1112377A4 (de) | 1998-06-22 | 1999-06-22 | Nukleinsäure-gekoppelte kolorimetrische analytdetektoren |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP1112377A4 (de) |
| WO (1) | WO1999067423A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1279023B1 (de) | 2000-03-20 | 2007-02-21 | Analytical Biological Services, Inc. | Verfahren zur erkennung eines analyten durch fluoreszenz |
| US7527981B2 (en) | 2002-05-09 | 2009-05-05 | Dennis Farwell | Bioweapon-detecting fibrous-network products and methods for making same |
| SE0201468D0 (sv) * | 2002-05-13 | 2002-05-13 | Peter Aasberg | Metod att använda luminescenta polymerer för detektion av biospecifik växelverkan |
| SE0401219D0 (sv) * | 2004-05-10 | 2004-05-10 | Biochromix Ab | Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter |
| US7816472B2 (en) | 2004-08-19 | 2010-10-19 | 3M Innovative Properties Company | Polydiacetylene polymer compositions and methods of manufacture |
| US7371511B2 (en) | 2004-08-19 | 2008-05-13 | 3M Innovative Properties Company | Polydiacetylene polymer blends |
| JP5008046B2 (ja) | 2005-06-14 | 2012-08-22 | ローム株式会社 | 半導体デバイス |
| US10577388B2 (en) | 2015-10-02 | 2020-03-03 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| CN117030688A (zh) * | 2023-03-24 | 2023-11-10 | 南京农业大学 | 一种基于智能手机检测土霉素残留的比色生物传感方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268305A (en) * | 1989-06-15 | 1993-12-07 | Biocircuits Corporation | Multi-optical detection system |
| WO1996008721A1 (en) * | 1994-09-13 | 1996-03-21 | Biocircuits Corporation | Direct and indirect modulation of spectrophotometric changes in lipid layer in measuring analytes |
| WO1997027316A1 (en) * | 1996-01-26 | 1997-07-31 | The Regents Of The University Of California | Polymeric film, assay and method for direct colorimetric detection of analytes |
| WO1998036263A1 (en) * | 1997-02-14 | 1998-08-20 | The Regents Of The University Of California | Protein-coupled colorimetric analyte detectors |
| WO1998039632A1 (en) * | 1997-03-03 | 1998-09-11 | The Regents Of The University Of California | Direct colorimetric detection of biocatalysts |
| WO1999010743A1 (en) * | 1997-08-29 | 1999-03-04 | Regents Of The University Of California | Sol-gel matrices for direct colorimetric detection of analytes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) * | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5412087A (en) * | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5512490A (en) * | 1994-08-11 | 1996-04-30 | Trustees Of Tufts College | Optical sensor, optical sensing apparatus, and methods for detecting an analyte of interest using spectral recognition patterns |
| AT401653B (de) * | 1994-10-05 | 1996-11-25 | Avl Verbrennungskraft Messtech | Verfahren zur immobilisierung biologischer komponenten in einer polymermatrix sowie biosensoren unter verwendung derartiger immobilisate |
| US5616790A (en) * | 1994-11-18 | 1997-04-01 | California Institute Of Technology | Lipid-based metal sensor |
-
1999
- 1999-06-22 EP EP99930522A patent/EP1112377A4/de not_active Withdrawn
- 1999-06-22 WO PCT/US1999/014029 patent/WO1999067423A1/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268305A (en) * | 1989-06-15 | 1993-12-07 | Biocircuits Corporation | Multi-optical detection system |
| WO1996008721A1 (en) * | 1994-09-13 | 1996-03-21 | Biocircuits Corporation | Direct and indirect modulation of spectrophotometric changes in lipid layer in measuring analytes |
| WO1997027316A1 (en) * | 1996-01-26 | 1997-07-31 | The Regents Of The University Of California | Polymeric film, assay and method for direct colorimetric detection of analytes |
| WO1998036263A1 (en) * | 1997-02-14 | 1998-08-20 | The Regents Of The University Of California | Protein-coupled colorimetric analyte detectors |
| WO1998039632A1 (en) * | 1997-03-03 | 1998-09-11 | The Regents Of The University Of California | Direct colorimetric detection of biocatalysts |
| WO1999010743A1 (en) * | 1997-08-29 | 1999-03-04 | Regents Of The University Of California | Sol-gel matrices for direct colorimetric detection of analytes |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9967423A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999067423A1 (en) | 1999-12-29 |
| EP1112377A1 (de) | 2001-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6306598B1 (en) | Nucleic acid-coupled colorimetric analyte detectors | |
| AU742885B2 (en) | Direct colorimetric detection of biocatalysts | |
| US6022748A (en) | Sol-gel matrices for direct colorimetric detection of analytes | |
| Reppy et al. | Biosensing with polydiacetylene materials: structures, optical properties and applications | |
| US20030129618A1 (en) | Sensitive and rapid detection of pathogenic organisms and toxins using fluorescent polymeric lipids | |
| US7183050B2 (en) | Gradient resolved information platform | |
| US20050181384A1 (en) | Selectivity of nucleic acid diagnostic and microarray technologies by control of interfacial nucleic acid film chemistry | |
| WO1999067423A1 (en) | Nucleic acid-coupled colorimetric analyte detectors | |
| EP1813948A1 (de) | Verfahren zum nachweis von zielsubstanzen | |
| CA2330937A1 (en) | Nucleic acid-coupled colorimetric analyte detectors | |
| JP2006523840A (ja) | 表面に固定された小胞の多層構造 | |
| US20050106596A1 (en) | Nucleic acid analysis methods conducted in small reaction volumes | |
| KR20010101092A (ko) | 운반체상에 dna를 고정화시키는 방법 | |
| WO1998036263A1 (en) | Protein-coupled colorimetric analyte detectors | |
| Patnaik et al. | Engineered polymer-supported synthesis of 3′-carboxyalkyl-modified oligonucleotides and their applications in the construction of biochips for diagnosis of the diseases | |
| AU748644B2 (en) | Nucleic acid-coupled colorimetric analyte detectors | |
| Maly et al. | Highly organized self-assembled dendriplexes based on poly (propylene imine) glycodendrimer and anti-HIV oligodeoxynucleotides | |
| AU2004227314B2 (en) | Surface immobilised multilayer structure of vesicles | |
| US8765369B2 (en) | Ultrasensitive detection of target using target-ready particles | |
| JP2009244101A (ja) | 被検物質の検出方法 | |
| Mazur | Bio-inspired Liposome-based Platforms for Biomedical Applications | |
| CN107109493A (zh) | 经由物理吸附将修饰的寡核苷酸固定至聚合物基体上 | |
| Vogel | DNA‐Controlled Assembly of Soft Nanoparticles | |
| Aruna et al. | Optimisation Studies for the Immobilization of Oligonucleotide Probe on Silica Nanoparticles | |
| Erdogan | p-Phenyleneethynylenes carrying biologically relevant ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20001227 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20040928 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20041215 |